

1 **Gabra5^{LHA} Mediate Astrocytic GABA-induced Obesity via Decreasing Energy**

2 **Expenditure**

3 **RUNNING TITLES:** Gabra5⁺ neurons facilitate energy expenditure

4

5 Moonsun Sa^{1,2}, Eun-Seon Yoo³, Wuhyun Koh², Mingu Gordon Park^{1,2}, Hyun-Jun Jang⁴, Yong Ryul

6 Yang⁴, Jiwoon Lim^{2,6}, Woojin Won^{1,2}, Jea Kwon^{1,2}, Mridula Bhalla^{2,6}, Heeyoung An², Yejin Seong², Ki

7 Duk Park⁵, Pann-Ghill Suh⁴, Jong-Woo Sohn³, C. Justin Lee^{1,2,6*}

8 ¹ KU-KIST Graduate School of Converging Science and Technology, Korea University, 145 Anam-ro,

9 Seongbuk-gu, Seoul, 02841, Republic of Korea

10 ² Center for Cognition and Sociality, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea

11 ³ Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, Republic
12 of Korea

13 ⁴ Ulsan National Institute of Science and Technology (UNIST), Ulsan, Republic of Korea

14 ⁵ Convergence Research Center for Diagnosis, Treatment and Care System of Dementia, Korea Institute of
15 Science and Technology (KIST), Seoul 02792, Republic of Korea.

16 ⁶ IBS School, University of Science and Technology (UST), Daejeon, Republic of Korea

17 *Correspondence: CJ Lee (cjl@ibs.re.kr)

18

19 **KEYWORDS:** GABA_A receptor $\alpha 5$, lateral hypothalamus, energy expenditure, reactive astrocytes,

20 gamma-aminobutyric acid, obesity

21 **SUMMARY**

22 The lateral hypothalamic area (LHA) regulates food intake and energy expenditure. Although
23 LHA neurons innervate adipose tissues, the identity of neurons that regulate fat is undefined. Here
24 we identify that Gabra5-positive neurons in LHA (Gabra5^{LHA}) polysynaptically project to brown and
25 white adipose tissues in the periphery. Gabra5^{LHA} are a distinct subpopulation of GABAergic
26 neurons and show decreased pacemaker firing in diet-induced obesity (DIO) mouse model. Gene-
27 silencing of Gabra5 in LHA decreases weight gain, whereas chemogenetic inhibition of Gabra5^{LHA}
28 suppresses energy expenditure and increases weight gain. In DIO mouse model, Gabra5^{LHA} are
29 tonically inhibited by nearby reactive astrocytes releasing GABA, which is synthesized by MAOB.
30 Administration of a MAOB inhibitor, KDS2010 reduces weight gain significantly without affecting
31 food intake, which is recapitulated by gene-silencing of astrocytic MAOB in LHA. We propose that
32 firing of Gabra5^{LHA} facilitates energy expenditure and selective inhibition of astrocytic GABA is a
33 molecular target for treating obesity.

34 INTRODUCTION

35 Obese people have an imbalance in food intake and energy expenditure which are
36 regulated by neural circuits which work inside the hypothalamus and extend beyond the
37 hypothalamus (Kong et al., 2012; Thaler et al., 2012). Hypothalamus consists of a number of small
38 nuclei which include LHA. Although LHA occupies an extended field of the hypothalamus, it is
39 substantially less anatomically defined (Bernardis and Bellinger, 1993; Flament-Durand, 1980;
40 Palkovits et al., 1980; Stuber and Wise, 2016). A subpopulation of LHA neurons are known to
41 innervate brown adipose tissue (BAT) and white adipose tissue (WAT) to mediate thermogenesis in
42 BAT, browning of WAT and energy storage in WAT (Cerri and Morrison, 2005; Contreras et al.,
43 2017). However, the precise cell types that innervate BAT and WAT to mediate thermogenesis and
44 energy storage are still under active investigation. The LHA contains several cell types expressing
45 different transmitters and hormones, including neurons expressing melanin-concentrating hormone
46 (MCH) and hypocretin/orexin (hcrtr/orx) (Bittencourt, 2011; Lee et al., 2021; Sakurai et al., 1998);
47 MCH neurons in LHA negatively regulate BAT activity to suppress energy expenditure (Oldfield et
48 al., 2002), whereas Orexin neurons send excitatory projections to increase BAT activity and energy
49 expenditure with decreasing in food intake (Berthoud et al., 2005; Contreras et al., 2015; Kakizaki et
50 al., 2019; Tupone et al., 2011; Zink et al., 2018). In addition, LHA contains other neurons that
51 express neither MCH nor Orexin (Backberg et al., 2004; Karnani et al., 2013; Kosse et al., 2017): A
52 large population of GABAergic neurons in LHA are intrinsically depolarized and distinct from MCH
53 and Orexin (Karnani *et al.*, 2013). These GABAergic neurons are defined by the presence of
54 components necessary for GABA synthesis and release, including GAD65, GAD67 and vesicular
55 GABA transporter (VGAT) (Bonnavion et al., 2016; Hassani et al., 2010; Jennings et al., 2013; Shin
56 et al., 2007). Due to their location in LHA, these neurons might function as critical regulators of
57 energy balance. However, the further classification and functional characterization of this vast
58 majority of GABAergic neurons in LHA are still unexplored (de Vrind et al., 2019). Furthermore, how
59 this heterogeneous population of GABAergic neurons in LHA interact with other cell types remains
60 poorly understood.

61 It has been reported that extracellular GABA level in mediobasal of hypothalamus becomes
62 elevated during chronic over-nutrition (Zhang et al., 2017). However, how this extracellular GABA is
63 synthesized and what causal role it plays in the pathogenesis of obesity and related metabolic
64 syndrome remains to be elucidated. We have previously shown that monoamine oxidase B (MAOB),
65 mainly expressed in astrocytes, synthesizes astrocytic GABA (Chun et al., 2018; Chun and Lee,
66 2018; Yoon et al., 2014). MAOB mediates degradation of polyamine putrescine, which is a
67 byproduct of toxin degradation, to generate GABA in astrocytes (Yoon *et al.*, 2014). Notably, MAOB
68 is elevated in transcriptionally profiled LHA cells in high fat diet (HFD)-fed mice in recent study
69 (Rossi et al., 2019). Astrocytes are known to be actively involved in the regulatory aspects of
70 metabolic control, such as feeding and brain glucose uptake (Bouyakdan et al., 2019; Chari et al.,
71 2011; Chen et al., 2016; Garcia-Caceres et al., 2016; Kim et al., 2014b; McDougal et al., 2013;
72 Varela et al., 2021; Yang et al., 2015). In addition to physiological condition, increasing lines of
73 evidence point to an involvement of hypothalamic astrocytes in the pathogenesis of DIO (Gonzalez-
74 Garcia and Garcia-Caceres, 2021). Reactive astrocytes are observed in several regions of
75 hypothalamus after HFD feeding (Buckman et al., 2013). Consumption of dietary fats also induce
76 metabolic damages on hypothalamic neurons, such as neuronal injury and a reduction of synaptic
77 inputs in LHA (Lizarbe et al., 2019; Moraes et al., 2009; Thaler *et al.*, 2012). However, how these
78 neuronal dysfunctions are mediated by GABA from reactive astrocytes in LHA remains elusive.
79 Furthermore, the role of reactive astrocytes in LHA as the controller of pathological processes by
80 over-nutrition still remains undetermined.

81 The released GABA from reactive astrocytes, as conventionally called tonic GABA, is
82 mediated by extrasynaptic GABA_A receptors in neighboring neurons (Yoon et al., 2012). Tonic
83 GABA reduces spike probability of granule cells in Alzheimer's disease (AD) mouse models (Jo et
84 al., 2014). Extrasynaptic GABA_ARs composed of $\alpha 5\beta\gamma 2$, $\alpha 4\beta\delta$, $\alpha 6\beta\delta$ and $\alpha 1\beta\delta$ subunits and are
85 located largely at extrasynaptic sites (Brickley and Mody, 2012; Caraiscos et al., 2004). It has been
86 previously demonstrated that $\alpha 5$ subunit of GABA_AR (Gabra5) shows moderate expression,
87 whereas δ subunit shows faint expression in LHA (Hortnagl et al., 2013). It has been further

88 demonstrated that Gabra5-positive neurons are distinct from MCH, orexin A and orexin B in LHA
89 (Thaler *et al.*, 2012). However, whether these Gabra5-positive neurons in LHA (Gabra5^{LHA}) are
90 GABAergic and their physiological role in energy expenditure and food intake are entirely unknown.

91 In this study, we hypothesized that Gabra5^{LHA} have regulatory role in energy balance by
92 interacting with astrocytes via gliotransmitter GABA. Based on genetic, pharmacological and
93 electrophysiological approaches, we found that Gabra5^{LHA} are a distinct sub-population of
94 pacemaker firing GABAergic neurons, regulating energy expenditure without affecting food intake
95 via astrocytic GABA in HFD-fed mice. Given these findings, we suggest that genetic and
96 pharmacological inhibition of excessive astrocytic GABA synthesis and GABA_A receptor containing
97 $\alpha 5$ subunit could be effective therapeutic strategies for obesity.

98

99 RESULTS

100 Pacemaker firing in GABAergic Gabra5^{LHA} is decreased in HFD mice

101 To identify and characterize functional roles of Gabra5^{LHA}, we developed Gabra5 promoter-
102 containing virus and injected AAV-mGabra5-eGFP-Cre into the LHA (Figures 1A and 1B). Next, we
103 performed immunohistochemical staining with antibodies against Gabra5, Orexin A, Orexin B, MCH
104 and GABA in LHA-injected slices to confirm the specificity of the promoter. Most of Gabra5
105 promoter-containing GFP-positive cells were overlapped with Gabra5 and GABA, but not with
106 Orexin or MCH (Figures 1C and 1D). These results suggest that Gabra5 promoter specifically target
107 Gabra5^{LHA} which are mostly GABA-producing neurons.

108 To investigate the intrinsic electrical properties of Gabra5^{LHA}, we used whole-cell patch-clamp
109 recordings in acute brain slices of AAV-Gabra5-eGFP-Cre injected mice (Figures 1E-1G).
110 Gabra5^{LHA} were spontaneously active in slice with near -50mV of resting membrane potential
111 (Figure 1H). We measured action potential (AP) wave forms for GFP-positive neurons, using
112 sustained current injection (Figure 1I). Gabra5^{LHA} were spiking at near-threshold membrane
113 potential and showed maximum firing frequency of ~76 Hz during maximal depolarization (Figure
114 1J). It has been previously shown that LHA GAD65 cells fall into four subtypes based on their

115 distinct electrical signatures with evoked firing: fast-spiking (FS), late-spiking (LS), low-threshold
116 spiking (LTS) and regular-spiking (RS) (Karnani *et al.*, 2013). Based on this categorization, we
117 characterized the firing patterns of Gabra5^{LHA} before and after a hyperpolarizing current step (Figure
118 1K). Approximately 66% of Gabra5^{LHA} showed increased firing frequency after the step by more
119 than 50% of that before the step. About 33% of Gabra5^{LHA} did not start firing immediately after the
120 step, but rather showed a slow ramp depolarization, resulting in a firing rate of less than 50% before
121 the step (Figures 1K and 1L). We found that Gabra5^{LHA} fell into two major subtypes based on
122 evoked firing: LS and LTS (Figure 1L). These results indicate that Gabra5^{LHA} are LS- and LTS-
123 subtypes of GAD65-positive GABAergic neurons in LHA.

124 To investigate the diet-induced changes in Gabra5^{LHA}, we performed loose cell-attached
125 patch clamping on Gabra5^{LHA} without disturbing the intracellular ionic concentration in acutely
126 prepared LHA slices from 8-week HFD-fed mice (Figure 1M). We found that the Gabra5^{LHA}
127 pacemaker firing rate was significantly decreased in HFD mice (Figures 1N and 1O). The decreased
128 firing rate was significantly restored by treatment with GABA_A receptor antagonist, bicuculline (50
129 μ M), in HFD mice (Figures 1P and 1Q). These results indicate that GABA-mediated inhibition
130 tonically suppresses the Gabra5^{LHA} pacemaker firing in HFD mice.




Figure 1. GABAergic Gabra5^{LHA}

show decreased activity in HFD.

(A and B) Experimental schema and

representative image for eGFP

neurons infected with AAV-Gabra5-

eGFP-cre in LHA (n=4 mice).

Bregma, -1.58 mm AP. Scale bar,

100 μm. (C) Quantification of

colocalized cell in eGFP neurons. (D)

Gabra5-eGFP is colored by green and

Gabra5, Orexin A, Orexin B,

MCH and GABA signals are colored

by Magenta. Robust colocalization of

eGFP with Gabra5 and GABA in

LHA. Few colocalization between

eGFP with Orexin A, Orexin B and

MCH. Left, representative image with

inset of region. Scale bar, 100 μm.

Right, magnification of ROI in LHA

131 **Chemogenetic inhibition of Gabra5^{LHA} suppresses energy expenditure**

132 We next investigated whether neuromodulation of Gabra5^{LHA} regulates body weight and food
133 intake by using chemogenetics to inhibit these neurons. We used the designer receptor exclusively
134 inhibited by designer drug (DREADD) hM4Di with a combination of AAV-mGabra5-eGFP-cre and
135 AAV-hSyn-DIO-hM4Di-mCherry viruses (Figures 2C and S31-D). After virus injection in LHA (Figure
136 2A), the mice were fed with HFD and administered with clozapine N-oxide (CNO) by drinking for 5
137 weeks (Figure 2B). Inhibition of Gabra5^{LHA} by drinking CNO led to a significant increase in body
138 weight and food intake starting from 4 weeks (Figures 2D-2F). Then we placed the mice in
139 metabolic cages to enable automated phenotyping of whole animal metabolic activity using the
140 comprehensive lab animal monitoring system (CLAMS). Inhibition of Gabra5^{LHA} led to a significant
141 decrease in total energy expenditure (Figures 2G and 2H), carbon dioxide production (Figures 2I
142 and 2J) and oxygen consumption (Figures 2K and 2L) in dark cycle without changes in locomotor
143 activity (Figures 2M and 2N). These results imply that Gabra5^{LHA} facilitate energy expenditure in
144 HFD mice. Then, we examined the expression of candidate genes which are related to
145 thermogenesis in adipose tissues by qRT-PCR analysis using reference gene as 18S ribosomal
146 RNA (Cannon and Nedergaard, 2004; Cero et al., 2021; Contreras *et al.*, 2015; Kurylowicz et al.,
147 2015; Orozco-Solis et al., 2016; Whittle et al., 2015). Consistent with the metabolic changes, we
148 found that Gabra5^{LHA} inhibition led to a significant decrease in iBAT mRNA levels of the uncoupling
149 protein *Ucp1*, *Cidea* and *Dio2*, but not *Prdm16*, *Pgc-1 α* (Figure 2O). There was a significant change
150 in the level of β -adrenergic receptor 3 (*Adrb3*) in WAT (Figure 2P). These genes are important
151 regulators of thermogenesis, browning and beiging of adipose tissue, and lipolysis (Cao et al., 2011;
152 Orozco-Solis *et al.*, 2016; Whittle *et al.*, 2015). Overall, these results suggest that chemogenetic
153 inhibition of Gabra5^{LHA} suppresses whole body energy expenditure with a reduced expression of
154 genes regulating thermogenesis and lipolysis.




Figure 2. Chemogenetic inhibition of Gabra5^{LHA} suppresses energy expenditure

(A and B) Experimental schema and timeline for Gabra5^{LHA} infected with inhibitory DREADD hM4Di. (C) Schematic diagram of Gabra5::mCherry (top) and Gabra5::hM4Di (bottom) viruses with AAV-Gabra5-eGFP-Cre virus. (D and E) Body weight on HFD with CNO drinking in gram (D) and in percentage (E). n = 7 mice per group. (F) Cumulative food consumption on HFD with CNO drinking. (G and H) Real-time monitoring curve of energy expenditure and quantification of energy expenditure in light and dark cycle. (I and J) Real-time monitoring curve and

quantification of carbon dioxide production in light and dark cycle. (K and L) Real-time monitoring curve and quantification of oxygen consumption in light and dark cycle. (M and N) Real-time monitoring curve and quantification of locomotor activity in light and dark cycle. Two-way ANOVA comparing Gabra5::mCherry and Gabra5::hM4Di with CNO drinking (n = 7 mice per group). (O) Molecular profiling of iBAT after chemogenetic inhibition of Gabra^{LHA} neurons. Genes tested: *Ucp1* (p < 0.05), *Cidea* (p > 0.05), *Prdm16* (p > 0.05), *Pgc-1α* (p > 0.05), *Dio2* (p < 0.05). n = 6 samples per group. (P) Molecular profiling of iWAT after chemogenetic inhibition of Gabra5^{LHA} neurons. Genes tested: *Ucp1* (p > 0.05), *Cidea* (p > 0.05), *Prdm16* (p > 0.05), *Pgc-1α* (p > 0.05), *Adrb3* (p < 0.05). n = 6 samples per group. Data represents Mean ± SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001.

156 **Gene-silencing of *Gabra5* in LHA reduces obesity**

157 To assess whether *Gabra5* regulates body weight and food intake, we employed gene-
158 silencing of *Gabra5* in LHA of HFD mice. We developed (Figures S2A-S2C) and injected lentivirus
159 carrying mouse *Gabra5*-specific short hairpin RNA (shRNA) into LHA (Figures 3A-3C), whose
160 knockdown efficiency was confirmed using immunohistochemistry (Figures S2D-S2F). Gene-
161 silencing of *Gabra5* (sh*Gabra5* group) showed a significant decrease in body weight after 5 weeks
162 of injection (Figure 3D), without affecting food intake compare to the control (Scrambled group)
163 (Figure 3F). To evaluate the changes of each peripheral organ with gene-silencing, we dissected
164 key organs (Figure 3E) and observed the weights of iWAT and perigonadal WAT (pWAT)
165 significantly decreased in sh*Gabra5* mice (Figure 3G). In contrast, the weights of liver, kidney,
166 spleen, heart and quadriceps were not different in sh*Gabra5* mice compared to Scrambled mice
167 (Figures 3E and 3G). BAT was slightly reduced in sh*Gabra5* mice, although it was not significantly
168 different (Figure 3H). To investigate the changes at the cellular level, we stained the adipose tissues
169 with hematoxylin and eosin (H&E). The adipocyte size of iWAT and pWAT were significantly
170 reduced in sh*Gabra5* mice (Figures 3I-3L). BAT histology also revealed significantly smaller lipid
171 droplets of adipocytes in sh*Gabra5* mice (Figures 3M and 3N). To define hepatic morphological
172 alteration caused by gene-silencing at the cellular level, we also observed hepatic cells using H&E
173 staining. There was no significant change of lipid droplet in the hepatic cells (Figures 3O and 3P).
174 Taken together, these results indicate that gene-silencing of *Gabra5* prevents adipose tissue-
175 specific weight increases with HFD.




Figure 3. Knockdown of Gabra5 in LHA reduces obesity

(A and B) Experimental schema and timeline for LHA injection. (C) Schematic diagram of Scrambled (top) and shGabra5 (bottom) viruses. (D) Curves of bodyweight in scrambled and shGabra5 mice.

Knockdown of Gabra5 in LHA reduces body weight in grams (n = 7-8 per group). (F) Average food intake per day in scrambled and shGabra5 mice. (E and G) Quantification of organ weight and representative images of each organ between scrambled and shGabra5 group (n = 6 per group). Scale bar, 1 cm. (H) Average weight of iBAT. (I and J) H&E of inguinal WAT (I) and quantified adipose size of iWAT (J) of scrambled and shGabra5 group (n = 6 mice per group). Scale bar, 100 µm. n=180, 262 cells, respectively. (K and L) H&E of perigonadal WAT (L), and quantified adipose size of pWAT (L) of scrambled and shGabra5 group (n = 6 mice per group). Scale bar, 100 µm. Scale bar, 100 µm. n=120, 180 cells, respectively. (M and N) H&E of interscapular BAT (M) and quantified adipocyte size of iBAT (N) of scrambled and shGabra5 group (n = 6 mice per group). Scale bar, 100 µm. Scale bar, 100 µm. n=392, 391 cells, respectively. (O and P) H&E of liver (O) and quantified triglyceride size of liver (P) of scrambled and shGabra5 group (n = 6 mice per group). Scale bar, 100 µm. n=732, 725 cells, respectively. (Q) Schema for identifying LHA neurons projecting polysynaptically to iBAT and iWAT. (R) Confocal images for PRV-infected cells in LHA at 5 days post-infection of PRV in iBAT and iWAT. Bregma, -1.58 mm AP. Scale bar, 100 µm. (S) Gabra5 is colored by magenta, and PRV-eGFP is colored by green. Top, representative IHC with inset of region. Scale bar, 50 µm. Bottom, magnification of ROI in LHA regions. Scale bar, 10 µm. (T and U) Quantification between Gabra5 and PRV retrogradely labeled from iBAT and iWAT 5 days post-injection (n = 3-4 mice per group). Data represents Mean ± SEM. *, p<0.05; **, p<0.01; ***, p<0.001.

176 **Gabra5^{LHA} polysynaptically project to BAT and WAT**

177 To determine whether Gabra5^{LHA} project to adipose tissues, we infected interscapular BAT
178 (iBAT) and inguinal WAT (iWAT) with a recombinant pseudo rabies virus (PRV) that enables
179 retrograde tracing of polysynaptically connected circuit (Bartness et al., 2005; Ryu et al., 2017;
180 Schneeberger et al., 2019). The mice were sacrificed 5 days after injection in iBAT and iWAT
181 (Figure 3Q). In previous studies, several brain regions were found to project to iBAT and iWAT,
182 including primary sensory cortex, paraventricular hypothalamus (PVH), periaqueductal gray (PAG),
183 LHA and raphe pallidus nucleus (RPa) (Ryu et al., 2015; Ryu *et al.*, 2017; Schneeberger *et al.*,
184 2019; You et al., 2020). Among these areas, we found that iBAT- or iWAT-projecting neurons were
185 detected in the medial, central and lateral part of the caudal LHA (Figures 3R and S3A). Then, we
186 performed immunohistochemistry to test whether iBAT- or iWAT-projecting neurons (eGFP-positive)
187 overlap with Gabra5-positive neurons within LHA. Interestingly, we found that ~30% of the iBAT-
188 projecting neurons and ~15% of the iWAT-projecting neurons overlapped with Gabra5 throughout
189 LHA (Figures 3S-3U). These results imply that Gabra5^{LHA} are responsible for polysynaptically
190 innervating iBAT and iWAT, which was further supported by the results from the tissue clearing and
191 light-sheet microscopic images (Figures S3B and S3C, Supplemental Video1).

192

193 **Reactive astrocytes in LHA in response to HFD**

194 Reactive astrocytes are observed in several regions of hypothalamus of HFD mice, such as
195 arcuate nucleus, medial preoptic, paraventricular and dorsomedial hypothalamus (Buckman *et al.*,
196 2013). Unlike other hypothalamic regions, reactive astrocytes in LHA are not defined yet. To define
197 the reactivity of astrocytes in LHA after 20 weeks of HFD, we performed immunohistochemistry to
198 examine the expression of astrocyte markers in LHA of HFD mice (Figures 4A and 4B). As a result,
199 astrocytes showed significantly hypertrophied signals in GFAP and S100 β (Figures 4C-4F). Volume
200 of GFAP-positive astrocytes significantly increased after 3D-rendering in HFD mice (Figures 4D and
201 4G). Sholl analysis of individual reactive astrocytes (Figure 4H) showed that the summation of
202 intersects (Figures 4I and 4J), ramification index (Figure 4K) and ending radius (Figure 4L), which is

203 an indicator of astrocytic territory, increased significantly in HFD compared to control. Therefore,
204 these results indicate that the astrocytes in LHA become reactive in response to HFD as evidenced
205 by the prominent morphological hypertrophy.

206 We have previously reported that A β plaques cause an increase in the activity of astrocytic
207 MAOB, which has been shown to produce GABA leading to a decreased neuronal activity in animal
208 models of AD model (Jo *et al.*, 2014). On the basis of this previous report, we hypothesized that
209 those reactive astrocytes in HFD mice would have high levels of MAOB and GABA. We performed
210 immunostaining in HFD mice and found that astrocytic MAOB signals were significantly increased
211 (Figures 4M and 4N). We also observed that astrocytic GABA in HFD mice was significantly
212 elevated (Figures 4O and 4P), with no change in neuronal Gabra5 level (Figures S3D and S3E).
213 Taken together, these results indicate that MAOB-mediated GABA in reactive astrocytes is
214 significantly increased in LHA of HFD mice.




Figure 4. Astrocytes in LHA show hypertrophy in response to HFD.

(A) Timeline of two different diet; chow diet and high fat diet group. (B and C) Coronal images of GFAP and s100β images in chow and HFD mouse in LHA. GFAP is colored by green and s100β is colored by cyan. Scale bar, 100 μm. (D) Significantly increased GFAP, s100β and 3D GFAP after HFD. Scale bar, 20 μm. (E - G) Quantification of GFAP intensity (E), S100β intensity (F) and GFAP-positive astrocyte volume (G) in chow and HFD mice.

Unpaired t test comparing treatments (n = 4 - 6 mice per group). (H) Representative image for Sholl analysis of an astrocyte in the LHA from the GFAP-stained image in D. The interval of the concentric circles is 1 μm. (I) The number of process intersections was significantly increased in GFAP+ astrocytes in the LHA of chow and HFD mice. (J and K) Number of summarized intersections (J) and ramification index (K) of GFAP+ astrocytes in chow and HFD mice. n = 381 - 411 cells per group, n = 4 - 6 mice per group. (L) The ending radius of GFAP+ astrocytes in LHA of chow and HFD mice. All data are the average of cells per slice; 2 slices per mouse. n = 4 - 6 mice per group. (M) Immunostaining for MAOB and GFAP in LHA of chow and HFD mice. Top, Scale bar, 10 μm. Bottom, magnification of ROI in LHA regions. Scale bar, 10 μm. (N) Quantification of MAOB intensity in GFAP+ astrocytes. n = 152 cells per group. n = 4 - 6 mice per group. (O) Immunostaining for GABA and GFAP in LHA of chow and HFD mice. Top, Scale bar, 20 μm. Bottom, magnification of ROI in LHA regions. Scale bar, 10 μm. (P) Quantification of GABA intensity in GFAP+ astrocytes. n = 338-367 cells per group. n = 4 - 6 mice per group. **, p < 0.01; ***, p < 0.001; ****, p < 0.0001

215

216

217

218

219

220

221

222 **Gene-silencing of astrocytic MAOB in LHA prevents obesity**

223 We then hypothesized whether astrocyte-specific gene-silencing of MAOB in LHA can
224 prevent DIO. To establish astrocyte-specific knockdown of MAOB, we used cre-dependent pSico-
225 shMAOB with astrocyte-specific GFAP-cre viruses in LHA (shMAOB group) and cre-dependent
226 pSico-Scrambled virus as control (Scrambled group) (Figures 5A and 5C). Their knockdown
227 efficiency was confirmed by immunohistochemistry in LHA (Figures S4A-S4C). Both groups were
228 fed with HFD (Figure 5B) and we found a significant reduction of astrocytic GABA in shMAOB group
229 (Figures 5D and 5E). In addition, shMAOB mice showed a significant decrease in body weight after
230 8 weeks of HFD feeding without affecting food intake (Figures 5F and 5G). We next analyzed and
231 compared the weights of each organ between shMAOB and Scrambled mice and found that
232 shMAOB mice exhibited a significant reduction of weight in iWAT, pWAT and BAT (Figures 5I-5J).
233 iWAT (Figures 5K and 5L), pWAT (Figures 5M and 5N) and BAT (Figures 5O and 5P) histology
234 revealed reduced lipid droplets in shMAOB mice compared to the Scrambled mice with no
235 significant change in the liver (Figures 5Q and 5R). Taken together, our results indicate that gene-
236 silencing of LHA-specific astrocytic MAOB reduces adipose tissue-specific weight thereby reducing
237 body weight without compromising appetite.




Figure 5. Knockdown of MAOB in LHA prevents obesity

(A and B) Experimental schema and timeline for LHA injection. (C) Schematic diagram of Scrambled (top) and shMAOB (bottom) viruses with GFAP-cre virus. (D and E) Representative immunostaining for Cre (mch), GFAP and GABA in LHA (D) and quantification of GABA intensity in GFAP+ astrocytes between scrambled and shMAOB mice. Scale bar, 20 μm . Scale bar, 10 μm . (F) Inhibition of MAOB targeting LHA reduces body weight in grams ($n = 7-8$ per group). (G) No difference is observed in average food intake per day. (H and I) Quantification of each organ weight and representative images of each organ between scrambled and shMAOB group ($n = 6$ per group). Scale bar, 1 cm. (J) Average weight of iBAT in scrambled and shMAOB group. (K and L) H&E of inguinal WAT (K) and quantified adipose size of iWAT (L) of scrambled and shMAOB group ($n = 6$ mice per group). Scale bar, 100 μm . $n = 138, 155$ cells, respectively. (M and N) H&E of perigonadal WAT (M) and quantified adipose size of pWAT (N) of scrambled and shMAOB group ($n = 6$ mice per group). Scale bar, 100 μm . $n = 114, 147$ cells, respectively. (O and P) H&E of iBAT (O) and quantified adipose size of iBAT (P) of scrambled and shMAOB group ($n = 6$ mice per group). Scale bar, 100 μm . $n = 580, 641$ cells, respectively. (Q and R) H&E of liver (Q) and quantified triglyceride size (R) of scrambled and shMAOB group ($n = 6$ mice per group). Scale bar, 100 μm . $n = 295, 569$ cells, respectively. Data represents Mean \pm SEM. *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$.

238 **Reducing GABA production via MAOB facilitates energy expenditure**

239 Finally, we tested that inhibition of astrocytic GABA synthesis can decrease body weight. To
240 test this hypothesis, we fed HFD to 6-week old C57BL/6J mice for 15 weeks till they reached near
241 50 g in bodyweight, after which they were treated with a recently developed a highly selective and
242 reversible MAOB inhibitor, KDS2010 (Park et al., 2019) (Figures 6A and 6B). We measured body
243 weight (Figures 6C and 6D) and food intake (Figure 6F) of chow, chow with KDS2010-treated, HFD
244 and HFD with KDS2010-treated mice every week (Figure 6E). We observed a significantly potent
245 decrease in body weight in KDS2010-treated HFD mice to the level of chow mice within 8 weeks
246 (Figure 6E) without changing their food intake (Figure 6F). In contrast, an irreversible MAOB
247 inhibitor Selegiline showed only a transient reduction in the body weight (Figures S5A-S5D). These
248 effects appear to be mainly through MAOB inhibition in the brain rather than peripheral system
249 (Figures S5E-S5H). We then examined the body composition of each group using EchoMRI for
250 measurement of fat and lean mass. There was a significant reduction only in fat mass (Figure 6G),
251 not in lean mass (Figure 6H). These results suggest that fat-specific weight loss is due to the MAO-
252 B inhibition by a reversible MAOB inhibitor in the brain.

253 Consistent with the fat mass reduction, we observed that the weights of iWAT, isWAT, pWAT
254 and BAT in HFD with KDS2010-treated mice (Figure S6A) were significantly reduced to that of chow
255 mice (Figures 6I and 6J). In addition to the reduction of fat mass, KDS2010 also reduced the weight
256 of liver induced by long-term treatment of HFD (Figure 6I). Then, we examined the tissues at the
257 cellular level using H&E staining. Consistent with the weight of each organ, histology of iWAT,
258 pWAT, and BAT revealed a significantly reduced size of adipocytes in HFD with KDS2010-treated
259 mice compared to HFD mice (Figures 6K-6N). Previous studies have shown that HFD induces
260 nonalcoholic fatty liver disease (Recena Aydos et al., 2019). There was a significant increase in
261 triglycerides in the liver in HFD mice, similar to the phenotype of fatty liver, which was significantly
262 reduced in HFD with KDS2010-treated mice (Figure 6O). Taken together, pharmacological inhibition
263 of MAOB with KDS2010 effectively and rapidly reduces obesity without affecting food intake.

264 To determine whether MAOB inhibition can promote energy expenditure, we measured
265 metabolic parameters using CLAMS. HFD with KDS2010-treated mice have significantly higher
266 energy expenditure (Figures 6P and 6Q), carbon dioxide production (Figures 6R and 6S) and oxygen
267 consumption (Figures 6T and 6U) than HFD mice in both light and dark cycle with no significant
268 difference in locomotor activity (Figures 6V and 6W). HFD with KDS2010-treated mice also showed
269 significantly improved glucose tolerance (Figures S6B and S6C) and insulin sensitivity compared to
270 HFD mice (Figures S6D and S6E). Overall, these results imply that pharmacological inhibition of
271 MAOB facilitates energy expenditure, leading to bodyweight decrease.




Figure 6. Reducing GABA production via MAOB increases energy expenditure and reduces obesity

(A) Four groups of different diet with drug treatment; chow diet with primary distilled water, chow diet with KDS2010, high fat diet with primary distilled water and high fat diet with KDS2010 treatment group. (B) Experimental timeline. (C and D) Representative images of each group mouse before sacrifice.

Average body weight of four groups ($n=5-7$ mice per group). Scale bar, 3 cm. (E) Curves representing the kinetics of change in body weight among chow, chow with KDS2010, HFD, HFD with KDS2010 mice over the 22 weeks following HFD treatment. Light blue box means KDS2010 treatment. $n=8$ mice per group. (F) Cumulative food intake in chow, chow with KDS2010, HFD, HFD with KDS2010 mice over the 22 weeks. $n=8$ mice per group. (G and H) Quantification of percentage change of fat mass

(G) and lean mass (H) at before (15 weeks) and after (22 weeks) KDS2010 treatment. (I and J) Quantification of organ weight (I) and average weight of iBAT (J) of chow, chow with KDS2010, HFD, HFD with KDS2010 group. (K - O) H&E of iWAT, pWAT, iBAT and liver (K). Scale bar, 100 μm . Quantified adipocyte size of iWAT (L), pWAT (M), iBAT (N) and liver (O) of chow, chow with KDS2010, HFD, HFD with KDS2010 group. (P - W) HFD with KDS2010 activate energy expenditure (P,Q), carbon dioxide production (R,S), oxygen consumption (T,U), but not in locomotor activity (V,W). $n=11, 11, 11$ and 8 for respective group. Data represents Mean \pm SEM. *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$.

272 **A reversible MAOB inhibitor reduces tonic GABA in LHA**

273 We observed that *Gabra5*^{LHA} pacemaker firing is suppressed by GABA-mediated inhibition in
274 HFD mice (Figures 1N and 1O). The mode of GABA action can be either phasic or tonic inhibition
275 (Bhattarai et al., 2011; Farrant and Nusser, 2005). So, we asked whether *Gabra5*^{LHA} is either
276 phasically or tonically inhibited in HFD mice. To test this possibility, we performed whole-cell patch-
277 clamp recordings in the acutely prepared LHA slices (Figure 7A). We assessed GABA_A receptor-
278 mediated phasic and tonic GABA currents by measuring the baseline current shift upon GABA_AR
279 antagonist, bicuculline, in the presence of ionotropic glutamate receptor antagonists, APV (50 μM)
280 and CNQX (20 μM), as described previously (Figures 7B-7E) (Jo et al., 2014; Lee et al., 2010). HFD
281 mice showed a significant increase of tonic GABA current compared to chow mice which was
282 reduced by KDS2010 treatment (Figure 7F). There was no significant difference in GABA-induced
283 full activation current which was induced by 10 μM GABA (Figure 7G). The amplitude and frequency
284 of spontaneous inhibitory post-synaptic currents (sIPSCs) were not significantly altered, indicating
285 that phasic or synaptic GABA was not altered (Figure 7H and 7I). The capacitance of LHA neurons
286 was not affected by HFD (Figure 7J). These results indicate that GABA action for *Gabra5*^{LHA} is
287 mediated by tonic inhibition and reversible KDS2010 significantly attenuated the tonic inhibition.

288 To examine the reactivity of astrocytes and astrocytic GABA level after KDS2010 treatment,
289 we performed immunostaining in LHA. We found that GFAP signals and GFAP-positive astrocyte
290 volume were significantly reduced in LHA of HFD with KDS2010-treated mice (Figures 7L and 7M)
291 compared to HFD mice. We also observed that the summation of intersects was significantly
292 reduced in HFD with KDS2010-treated mice (Figure 7N). As expected, we found that MAOB
293 expression in astrocyte was significantly reduced in LHA of HFD with KDS2010-treated mice
294 compared to HFD mice (Figures S6F and S6G). To test whether inhibition of MAOB reduces the
295 GABA level in astrocytes, we performed immunostaining and found that astrocytic GABA signals
296 were significantly reduced in HFD with KDS2010-treated mice compared to that of HFD mice
297 (Figure 7O). Taken together, these results indicate that MAOB inhibition by the reversible inhibitor

298 KDS2010 reduces astrocytic reactivity and GABA level in LHA, thereby attenuating tonic inhibition
299 of LHA neurons in HFD mice.




Figure 7. A reversible MAOB inhibitor reduce extrasynaptic GABA in LHA.

(A) Schema of whole cell patch clamp recording in LHA neurons. (B - E) Representative traces of GABA_A receptor-mediated currents recorded from LHA neurons of chow diet (B), chow diet with KDS2010 (C), high fat diet (D), high fat diet with KDS2010 (E) group. Each dot represents one cell (n = 6, 3, 8, and 3 mice, respectively). BIC 50uM, GABA 10uM. (F) GABA_A

receptor-mediated tonic GABA current measured from LHA neurons in each group. (G) GABA-induced full activation current measured from LHA neurons in each group. (H and I) Frequency and amplitude of sIPSC measured from LHA neurons in each group. (J) Capacitance of LHA neurons in each group. (K) Top, Immunostaining for GABA and GFAP in LHA of chow, chow with KDS2010, HFD and HFD with KDS2010 group. Scale bar, 20 μ m. Bottom, magnification of ROI. 3D rendering GFAP with GABA immunostaining. Scale bar, 10 μ m. (L) Quantification of GFAP intensity in GFAP⁺ astrocytes. n = 438, 222, 294 and 112 cells per group. n = 4 - 6 mice per group. (M) Quantification of volume of GFAP⁺ astrocytes. n = 89, 69, 179 and 117 cells per group. n = 4 - 6 mice per group. (N) Number of summarized intersections of GFAP⁺ astrocytes in each group. n = 128, 94, 169 and 205 cells per group, n = 4 - 6 mice per group. (O) Quantification of GABA intensity in GFAP⁺ astrocytes. n = 104, 91, 160 and 113 cells per group. n = 4 - 6 mice, respectively. Data represents Mean \pm SEM. *, p < 0.05, **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.

300 **DISCUSSION**

301 In the present study, we have discovered the existence of a unique population of energy
302 expenditure-facilitating neurons in LHA. These neurons are uniquely expressing the high-affinity
303 extrasynaptic GABA_A containing Gabra5 subunit and at the same time GABA-producing, *i.e.*,
304 GABAergic Gabra5^{LHA}. Although GABAergic, these neurons appear to be projection neurons,
305 projecting polysynaptically to iBAT and iWAT. These neurons show unique electrical properties of
306 low-threshold spiking and pacemaker firing at a firing frequency of around 5 Hz. The presence of
307 Gabra5 allows sensing of tonically released low concentration of extrasynaptic GABA, which has
308 been recently characterized to be synthesized by MAOB and released by reactive astrocytes under
309 pathological conditions such as in Alzheimer's disease and Parkinson's disease (Jo *et al.*, 2014;
310 Park *et al.*, 2019). We have also demonstrated for the first time the causal relationship between
311 reactive astrocytes and thermogenesis/fat storage in DIO mouse model via the complex GABA
312 signaling in LHA, composed of increase in astrocytic tonic GABA, activation of neuronal GABA_A
313 receptors containing $\alpha 5$ subunit, reduction in pacemaker firing in Gabra5^{LHA}, attenuation of
314 thermogenesis and augmentation of fat storage in peripheral adipose tissues (Figure S7A). These
315 cascade of events in DIO model can be mimicked by activation of Gi-DREADD expressed in
316 Gabra5^{LHA} and reversed by pharmacological inhibition or gene-silencing of MAOB to reduce
317 astrocytic GABA and gene-silencing of Gabra5 to reduce tonic GABA inhibition in Gabra5^{LHA} (Figure
318 S7B). Strikingly, this reversal of DIO can be achieved without compromising appetite. Our study
319 proposes the pathological role of glia-neuron interaction via astrocytic GABA and neuronal Gabra5
320 and its contribution to thermogenesis/fat storage and DIO with minimal contribution to food intake.

321

322 **GABAergic Gabra5^{LHA} innervate BAT or WAT**

323 Recent research highlights that LHA lacks inhibitory interneurons with locally ramifying
324 axons (Burdakov and Karnani, 2020). This suggests that the GABAergic neurons in LHA project to
325 outside of LHA rather than locally inhibit the nearby neurons. LHA contains a large number of
326 GABAergic neurons expressing GAD65, GAD67 and VGAT (Elias *et al.*, 2008; Harthoorn *et al.*,

2005; Jennings *et al.*, 2013; Jennings *et al.*, 2015; Karnani *et al.*, 2013). These neurons are likely to be highly diverse and subdivided into many subpopulations with distinct characteristics and functions. In the current study we have identified that GABAergic Gabra5^{LHA} project to outside of LHA and polysynaptically innervate iBAT and iWAT. LHA regulates both thermogenesis and lipolysis in brown adipocytes through the sympathetic nervous system (SNS) (Bamshad *et al.*, 1999; Bartness *et al.*, 2010; Cannon and Nedergaard, 2004; Contreras *et al.*, 2017). LHA also regulates lipolysis of iWAT through SNS (Bartness *et al.*, 2010; Cannon and Nedergaard, 2004; Richard and Picard, 2011). It has been reported that in mice injected with PRV into iBAT, PRV-infected neurons in LHA overlap with MCH and Orexin (Izawa *et al.*, 2021). However, there is still a remaining undefined population that innervates iBAT and iWAT in LHA. We propose that the remaining population is in part GABAergic Gabra5^{LHA}. In previous studies, Orexin^{LHA} were shown to project to rostral raphe pallidus (rRPa) in the brainstem (Contreras *et al.*, 2017; Tupone *et al.*, 2011), which are known as sympathetic premotor neurons to control sympathetic output and activate iBAT (Morrison *et al.*, 2014). Consistently, viral tracing evidence further demonstrates that sympathetic nerves that innervate subcutaneous WAT originate from rRPa (Nguyen *et al.*, 2014), which then project to sympathetic preganglionic neurons in the spinal intermediolateral nucleus (IML) (Morrison *et al.*, 2012). Our results from the tissue clearing and light-sheet microscopic images suggest that GABAergic Gabra5^{LHA} might project to PAG before reaching to rRPa (Figure S3C). We propose that GABAergic Gabra5^{LHA}, just like Orexin^{LHA}, may also project to rRPa possibly after passing through PAG and innervate iBAT and iWAT through IML and sympathetic ganglion. Future investigations are needed to determine the exact polysynaptic circuits for GABAergic Gabra5^{LHA}, projecting to iBAT and iWAT.

350 **Astrocytic GABA suppresses the activity of Gabra5⁺ neurons**

351 Our study sheds a light on the missing link between the reactive astrogliosis and obesity,
352 delineating the molecular and cellular mechanisms of how MAOB-dependent production of GABA
353 leads to inhibition of energy expenditure and facilitation of fat storage. Elevated activity of MAOB and

354 elevated levels of MAOB-dependent GABA have been highly implicated in the reactive astrocytes that
355 are found in various neuroinflammatory diseases such as Alzheimer's disease, Parkinson's disease,
356 stab-wound injury model and et cetera (Chun et al., 2021; Jo *et al.*, 2014; Nam et al., 2021; Pandit et
357 al., 2020; Shim et al., 2019). The growing list of reports all point to the common molecular mechanism
358 of how resting astrocytes transform into reactive astrocytes via the putrescine-degradation pathway
359 involving MAOB under the conditions of aversive stimulations such as toxin challenges and viral
360 infections, which usually accompany neuroinflammation (Chun *et al.*, 2018). In the current study, we
361 have also discovered the same common molecular mechanism at work in LHA to cause the reactive
362 astrogliosis and the production of GABA in MAOB-dependent fashion. Then, what is the toxin that
363 turns on this mechanism in LHA? It has been reported that chronic HFD induces hypothalamic
364 inflammation, which is associated with reactive astrocytes in the hypothalamus (Thaler *et al.*, 2012),
365 raising a possibility that the high fat nutrition itself could be the trigger for reactive astrogliosis and
366 GABA-production. Indeed, we have recently found that astrocytes in culture start to produce GABA
367 when they are challenged with elevated levels of fatty acids (Lee et al., 2018). Consistent with our
368 findings, it has been reported that after chronic overnutrition, extracellular neurotransmitters such as
369 GABA levels become elevated in mediobasal of hypothalamus (Zhang *et al.*, 2017). In this study, we
370 have further demonstrated that the MAOB-dependent astrocytic tonic GABA induces a strong
371 neuronal inhibition in *Gabra5*^{LHA}. In addition, the MAOB-dependent H₂O₂ has been recently implicated
372 in neurodegeneration and brain atrophy in Alzheimer's disease (Chun et al., 2020b). Although we
373 have not investigated further, we expect that the reactive astrocytes in LHA would produce excess
374 amount of toxic H₂O₂ in MAOB dependent fashion, further exacerbating the reactive astrogliosis. The
375 excess amount of toxic H₂O₂ would cause neuronal death of the neighboring neurons in LHA under
376 chronic obesity condition. Indeed, consumption of dietary fats induce apoptosis of neurons and a
377 reduction of synaptic inputs in LHA (Moraes *et al.*, 2009). This possibility of H₂O₂-induced
378 neurodegeneration in LHA awaits future investigation.

379

380 **KDS2010, a reversible MAOB inhibitor, as a new therapeutic strategy for anti-obesity drug**
381 **development**

382 Our study add a new dimension to the existing anti-obesity drugs. It has been reported in previous
383 studies that drugs for weight loss have a significant history of safety risks, including cardiovascular
384 and psychiatric complications (Cheung *et al.*, 2013; Kim *et al.*, 2014a). Most of the obesity drugs that
385 target neurons in the hypothalamus are known to suppress appetite rather than to increase energy
386 expenditure (Cheung *et al.*, 2013). Based on our study, we propose that selective inhibition of MAOB
387 may be potential molecular targets for treating obesity to overcome the limitations of neuron-target
388 obesity drugs. By using three pharmacological inhibitors, KDS2010, KDS1524, and selegiline, with
389 differential properties, we have gained useful insights about designing effective therapeutic strategies.
390 By comparing the irreversible inhibitor selegiline and reversible inhibitor KDS2010, we discovered that
391 KDS2010 showed long-lasting effects compared to selegiline, implying that reversibility of MAOB
392 inhibitor is critical for long-lasting efficacy. These results are consistent with our previous reports on
393 the superior effect of reversible MAOB inhibitors on animal models of Alzheimer's disease and
394 Parkinson's disease (Nam *et al.*, 2021; Park *et al.*, 2019). Furthermore, by comparing the BBB-
395 permeable KDS2010 and the less BBB-permeable KDS1524, we discovered that KDS2010 showed
396 a far superior effect than KDS1524, implying that the central MAOB in the brain is a far more effective
397 target for developing anti-obesity drug than the peripheral MAOB. The effect of inhibiting MAOB in
398 the brain can also affect other hypothalamic regions, such as acute nucleus and PVH, where reactive
399 astrocytes are readily observed after HFD (Buckman *et al.*, 2013). This could explain why KDS2010
400 treatment showed a much steeper weight loss than the LHA-specific MAOB gene-silencing. KDS2010
401 treatment should ameliorate the aberrant reactive astrogliosis and tonic GABA inhibition throughout
402 the various hypothalamic regions, thus eliminating the undesirable inhibition of neuronal activity. It
403 would be interesting to investigate the existence and physiological roles of Gaba5-positive neurons
404 in other hypothalamic regions. The difference in the long-term efficacy between selegiline and
405 KDS2010 has been mechanistically explained by how reversible and irreversible inhibitors
406 differentially act on the MAOB enzyme; irreversible inhibitors like selegiline covalently modify the

407 MAOB enzyme and destroy the enzyme itself to turn-on the compensatory mechanism of DAO,
408 whereas reversible inhibitors occupy the active site of MAOB competitively, resulting in an intact
409 MAOB enzyme with no compensatory mechanism (Park *et al.*, 2019). More importantly, selective
410 inhibition of MAOB does not affect food intake and appetite. These novel features of MAOB inhibitors
411 will help develop better anti-obesity drugs in the future.

412 In summary, we propose that Gabra5^{LHA} are distinct GABAergic-projecting and pacemaker-
413 firing neurons which facilitate energy expenditure through adipocyte tissues. These findings
414 establish the Gabra5^{LHA} as key players modulating GABA via astrocyte-neuron interaction in
415 hypothalamus of DIO mouse model. Our study raises new molecular targets to combat obesity
416 without compromising appetite.

417

418 **Author contributions**

419 MS Sa, ES Yoo, W Koh, MG Park, HJ Jang, YR Yang, J Lim, W Won, J Kwon, M Bhalla, H
420 A, Y Seong performed experiments. KD Park, PG Suh, JW Sohn, CJ Lee supervised the
421 analysis. MS Sa and CJ Lee wrote the manuscript.

422

423 **Acknowledgements**

424 This work was supported by the Institute for Basic Science (IBS), Center for Cognition and
425 Sociality (IBS-R001-D2). This study was also supported by the National Research
426 Foundation (NRF) Grants from the Korean Ministry of Education, Science and Technology
427 (2018M3C7A1056894, NRF-2020M3E5D9079742) and KIST Grants (2E30954 and
428 2E30962).

429

430 **Declaration of interests**

431 The authors declare that there is no conflict of interests.

432 **STAR Methods**

433 **RESOURCE AVAILABILITY**

434 ***Lead contact***

435 Further information and requests for resources and reagents should be directed to and will be
436 fulfilled by the lead contact Dr. C Justin Lee (cjl@ibs.re.kr)

437 ***Materials availability***

438 The sequences of the shRNAs used in this study have been provided in the Supplementary figures.

439 The viruses used in this study were provided by and are available with the Institute for Basic
440 Science Virus Facility (<https://www.ibs.re.kr/virusfacility>) and Korea Institute of Science and
441 Technology Virus Facility upon request (<http://virus.kist.re.kr>).

442 ***Data and code availability***

443 Accession number is listed in the Key Resources Table. Microscopy data reported in this paper will
444 be shared by the lead contact upon request. This paper does not report any original code. Any
445 additional information required to reanalyze the data reported in this paper is available from the lead
446 contact upon request.

447

448 **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

449 **Animals and housing**

450 All animal experiments were performed according to procedures approved by the Institutional
451 Animal Care and Use Committee of IBS (Daejeon, South Korea) and Korea Institute of Science and
452 Technology (Seoul, South Korea). All mice were maintained in a specific pathogen-free animal
453 facility under a 12-h light-dark cycle (lights on at 8:00 AM) at a temperature of 21°C and allowed
454 free access to water and food. All experiments performed on diet-induced obesity (DIO) mouse
455 model were performed on C57BL/6J background were used originated from Jackson Laboratory
456 (USA, stock number 000664). 6-week-old male C57BL/6J mice (DBL, Chungbuk, Republic of
457 Korea) were fed a HFD (60% kcal fat, D12492, Research Diets Inc.) or chow (Teklad, 2018S,
458 Envigo) for 6~23 weeks. All experiments were done with age-matched controls.

459

460 **Stereotaxic injection**

461 Mice were anesthetized using isoflurane anesthesia (induction: 3%–4%, maintenance: 1.5%–2%)
462 and placed into stereotaxic frames (Kopf). The scalp was incised and a hole was drilled into the
463 skull above the LHA (anterior/posterior, -1.58 mm; medial/lateral, -1.0 or +1.0 mm from bregma).
464 Coordinates were identified using the Allen mouse brain atlas. For characterization studies,
465 C57BL/6J mice were injected with 1.0 μ L of AAV-mGabra5-eGFP-cre virus in the LHA. For Gabra5
466 knockdown studies, C57BL/6J mice were injected with 1.0 μ L of Lenti-pSicoR-Gabra5 shRNA-
467 mCherry or Lenti-Scrambled-mCherry virus in the LHA. For chemogenetic studies, AAV5-mGabra5-
468 eGFP-Cre with AAV5-hSyn-DIO-hM4Di-mCherry (inhibition) or AAV5-hSyn-DIO-mCherry (control
469 virus) were used in the LHA. For astrocyte-specific MAOB knockdown studies, AAV-GFAP-mCherry
470 with Lenti-pSico-Scrambled-GFP or Lenti-pSico-shMAOB-GFP virus were used in the LHA. The
471 virus was loaded into a stainless needle and injected bilaterally into the LHA (dorsal/ventral, -5.0
472 mm) at a rate of 0.1 μ lmin⁻¹ for 10 min using a syringe pump (KD Scientific). At the end of the
473 infusion, the needle was left in the brain for another 10 min to reduce backflow of the virus. Shortly
474 after surgery, mice were translocated to their home cages.

475

476 **Slice preparation for electrophysiology**

477 Mice were deeply anaesthetized with vaporized isoflurane and then decapitated to isolate the brain.
478 The isolated brains were quickly excised from the skull and submerged in ice-cold NMDG recovery
479 solution containing: 93 mM of NMDG, 93 mM of HCl, 30 mM of NaHCO₃, 20 mM of HEPES, 25 mM
480 Glucose, 5 mM sodium ascorbate, 2.5 mM KCl, 1.2 mM NaH₂PO₄ (pH 7.4.). All the solution was
481 gassed with 95% O₂ and 5% CO₂. The brain was glued onto the stage of a vibrating microtome
482 (Linear Slicer Pro7, D.S.K) and 250- μ m-thick coronal slices were prepared. For stabilization, slices
483 were incubated in room temperature for at least 1 h in extracellular aCSF solution containing 130
484 mM of NaCl, 3.5 mM of KCl, 24 mM of NaHCO₃, 1.25 mM of NaH₂PO₄, 1.5 mM of CaCl₂, 1.5 mM of

485 MgCl₂, and 10 mM of d-(+)-glucose, pH 7.4. and simultaneously equilibrated with 25°C. Slices were
486 transferred to a recording chamber that was continuously perfused with aCSF solution.

487

488 **Patch-clamp recording**

489 For the characterization of Gabra5^{LHA} cells, electrophysiological experiments were conducted with
490 reference to previous study (Karnani *et al.*, 2013). Patch electrodes (4-8 MΩ) were filled with an
491 intrapipette solution containing: 120 mM of potassium gluconate, 10 mM of KCl, 1 mM of MgCl₂, 0.5
492 mM of EGTA and 40 mM of HEPES (pH 7.2 adjusted with KOH). Resting membrane potential (mV)
493 was measured at I=0 soon after membrane rupture. Step current was injected in current clamp
494 mode to measure maximum firing frequency (Hz), which is the reciprocal of the average of the first
495 four peak intervals (ISI) calculated after the highest injected current before the occurrence of spike
496 inactivation. Spike ratio was determined by calculating X/(Y/2) from the number of spikes before
497 (500 ms window, Y) and after (250 ms window, X) hyperpolarization by negative current step.
498 Classification of cells, which is late spiking for <0.5, regular spiking for between 0.5 and 1.5, low-
499 threshold spiking for >1.5 followed previous study (Karnani *et al.*, 2013). For the measurement of
500 spontaneous spike activity in Gabra5^{LHA}, cell-attached patch was conducted as previously described
501 (Heo *et al.*, 2020). Patch electrodes (4-8 MΩ) were filled with normal aCSF solution. The slice
502 chamber was mounted on the stage of an upright microscope and viewed with a 60x water
503 immersion objective (numerical aperture = 0.90) with infrared differential interference contrast
504 optics. Cellular morphology was visualized by a complementary metal oxide semiconductor camera
505 and the Imaging Workbench software (INDEC BioSystems, ver. 9.0.4.0.).

506

507 **Tonic GABA recording**

508 Whole-cell patch clamp recording was conducted as previously described (Jo *et al.*, 2014). The
509 holding potential was -60 mV. Pipette resistance was typically 6–8 MΩ and the pipette was filled
510 with an internal solution consisting of: 135 mM of CsCl, 4 mM of NaCl, 0.5 mM of CaCl₂, 10 mM of
511 HEPES, 5 mM of EGTA, 2 mM of Mg-ATP, 0.5 mM of Na₂-GTP, and 10 mM of QX-314, pH-

512 adjusted to 7.2 with CsOH (278–285 mOsmol). Before measuring the tonic current, the baseline
513 current was stabilized with D-AP5 (50 μ M) and CNQX (20 μ M) to isolate GABA_A receptor current
514 from AMPAR and NMDAR. Electrical signals were digitized and sampled at 10-ms intervals with
515 Digidata 1550 data acquisition system and the Multiclamp 700B Amplifier (Molecular Devices) using
516 the pClamp10.2 software. Data were filtered at 2 kHz. The amplitude of the tonic GABA current was
517 measured by the baseline shift in response to the bath application of bicuculline (50 μ M) using the
518 Clampfit software (ver. 10.6.0.13.). The frequency and amplitude of spontaneous inhibitory
519 postsynaptic currents before bicuculline administration was detected and measured by Mini
520 Analysis (Synaptosoft, ver. 6.0.7.)

521

522 **Immunohistochemistry**

523 Mice were deeply anaesthetized with isoflurane and transcardially perfused with 0.9% saline
524 followed by ice-cold 4% paraformaldehyde (PFA). Excised brains were postfixed overnight at 4°C
525 and transferred to 30% sucrose for 48 hours and cut with a frozen microtome in coronal 30 μ m
526 sections. Brain sections were translocated into 24-well plates filled with blocking solution (0.3%
527 Triton X-100, 3% Donkey Serum in 0.1M PBS). Primary antibodies were added to blocking solution
528 at desired dilution and slices were incubated in a shaker at 4°C overnight. Primary antibodies for
529 immunostaining were anti-Gabra5 (rabbit, 1:200), Orexin A (rabbit, 1:100), Orexin B (rabbit, 1:500),
530 MCH (rabbit, 1:200), GABA (rabbit, 1:200), GFAP (chicken, 1:500), S100 β (rabbit, 1:200), MAOB
531 (mouse, 1:100), NeuN (mouse or guinea pig, 1:500) and c-Fos (rabbit, 1:500). Antibody details can
532 be found in the Key Resources Table. Unbound antibodies were washed off using PBS, followed by
533 corresponding secondary antibody incubation (in blocking solution) for 1 or 2 hours at room
534 temperature. Unbound antibodies were washed with PBS and DAPI was added to PBS (1:1500
535 dilution) in the second step to visualize the nuclei of the cells. Sections were mounted with
536 fluorescent mounting medium (Dako) and dried. Series of fluorescent images were obtained by
537 Zeiss LSM900 confocal microscope using a 20x, 40x, or 63x objective. Z stack images were

538 processed using the ZEN Digital Imaging for Light Microscopy blue system (Zeiss, ver. 3.2) and
539 ImageJ (NIH, ver. 1.52s.) software.

540

541 **Image quantification**

542 Confocal microscopic images were obtained in order to quantify the number of colocalized cells and
543 expression were analyzed using the ImageJ (NIH) program. Fluorescence intensities were
544 calculated using the mean intensity value of each fluorescence pixels in the marker-positive area.
545 The marker-positive area was defined by thresholding and is converted into a binary mask. The
546 mean intensity of immunostained pixels in the binary mask was calculated. Sholl analysis was
547 performed on serially stacked and maximally projected confocal images as previously described
548 (Chun et al., 2020a). Confocal images of brain sections immunostained with GFAP antibody were
549 used for Sholl analysis. The Sholl analysis plugin applied in IMARIS constructs serially concentric
550 circles at 10 μ m intervals from the center of GFAP signal (soma) to the end of the most distal
551 process of each astrocyte. The number of intercepts of GFAP-positive processes at each circle and
552 the radius of the largest circle intercepting the astrocyte are analyzed.

553

554 **Tissue isolation and histological analysis**

555 Mice were deeply anesthetized with isoflurane and organs were immediately isolated from the mice
556 body. we isolated inguinal white adipose tissues (iWAT), interscapular white adipose tissue
557 (isWAT), perigonadal white adipose tissue (pWAT), mesenteric white adipose tissue (mWAT), Liver,
558 quadriceps muscle (Quad), kidney, spleen, and heart. After measuring the weight of each organ,
559 iBAT, iWAT, pWAT and Liver tissues were fixed with 4% PFA (Sigma- Aldrich, St. 538 Louis, MO)
560 for overnight and conducted further processes. Histological changes of lipid droplets were examined
561 by hematoxylin and eosin (H&E) staining. As counterstain, Mayer's hematoxylin was used for every
562 slide. Images were obtained with Eclipse TI-E microscope.

563

564 **Tissue clearing and light-sheet imaging**

565 Mice were transcardially perfused with ice-cold PBS and then with the SHIELD perfusion solution
566 (Passive clearing, Lifecanvas, 500ml kit - Cat. No. PCK-500) as described previously (Park et al.,
567 2018). Dissected brains were incubated in the same perfusion solution at 4 °C for 48 h. Tissues
568 were then transferred to the SHIELD-OFF solution and incubated at 4 °C for 24 h. Following the
569 SHIELD-OFF step, brains were placed in the SHIELD-ON solution and incubated at 37 °C for 24 h.
570 SHIELD-fixed brains were cleared passively for a couple of weeks (10–14 d at 45 °C for a mouse
571 brain hemisphere) in buffer solution. Delipidated tissues were incubated in Protos-based immersion
572 media until the tissue became transparent without any visible haze at the tissue–medium interface.
573 3D light-sheet images were taken by Zeiss Light sheet Fluorescence microscopy (LSFM) 7.

574

575 **Metabolic analysis**

576 After measuring body weight and food intake, the energy expenditure of these mice was measured
577 using the Comprehensive Lab Animal Monitoring System (CLAMS, Columbus Instruments). The
578 mice were individually acclimated to the metabolic chamber cage before measuring energy
579 expenditure for at least 5 days, and then data were collected for another 24 hours. Mice are allowed
580 to access freely to water and food. For Glucose tolerance test (GTT), mice were fasted overnight
581 (18 h) before intraperitoneal injection of D-glucose (2 g/kg body weight). Subsequently, the
582 clearance of plasma glucose was monitored following glucose administration. For insulin tolerance
583 test, mice were fasted for 4 h before intraperitoneal injection of insulin (0.75 U/kg body weight).
584 Every glucose was examined with tail-vein blood at indicated intervals (15, 30, 60, 90 and 120 min)
585 after injection using a glucometer. For analyzing metabolic parameters, insulin (90080, Crystal
586 Chem, Elk Grove Village, IL) were determined. For body composition measurement, fat and lean
587 mass of each mouse in this study were measured by an EchoMRI100V, quantitative nuclear
588 resonance system (Echo Medical Systems, Houston, TX).

589

590 **Designer Receptors Exclusively Activated by Designer Drugs (DREADD) experiments**

591 For DREADD experiments, 6 to 7 weeks old mice were injected either AAV-hSyn-DIO-mCherry or
592 AAV-hSyn-DIO-hM4Di-mCherry with AAV-mGabra5-eGFP-Cre (3.8×10^{13} GC/ml) into the lateral
593 hypothalamus of C57BL/6J. Following a recovery period of 3 weeks, Mice were given 5mg/kg/day
594 CNO in drinking and high-fat diet food (TD 06414, Envigo) for 5 weeks in order to measure body
595 weight and food consumption every week. CNO was dissolved in distilled water and protected from
596 the light.

597

598 **Quantitative real-time RT-PCR.**

599 Quantitative real-time RT-PCR was carried out using SYBR Green PCR Master Mix as described
600 previously (Kwak et al., 2020). Briefly, reactions were performed in triplets in a total volume of 10 μ
601 containing 10pM primer, 4 μ l cDNA, and 5 μ l power SYBR Green PCR Master Mix (Applied
602 Biosystems). The mRNA level of each gene was normalized to that of 18s mRNA. Fold-change was
603 calculated using the $2^{-\Delta\Delta CT}$ method. The following sequences of primers were used for real-time
604 RT-PCR. The followings are the sequences of utilized primers.

605 18S forward: 5'- TGGCTC ATTAATCAGTTATGGT -3'; 18S reverse: 5'-
606 GTCGGCATGTATTAGCTCTAG -3'.

607 Ucp1 forward: 5'- ACTGCCACACCTCCAGTCATT -3'; Ucp1 reverse: 5'-
608 CTTTGCCTCACTCAGGATTGG -3'.

609 Cidea forward: 5'- TTCAAGGCCGTGTTAAGGAATC -3'; Cidea reverse: 5'-
610 CCAGGAACTGTCCCGTCATC - 3'.

611 Prdm16 forward: 5'- CAGCACGGTGAAGCCATTC -3'; Prdm16 reverse: 5'-
612 GCGTGATCCGCTTGTG -3'

613 Pgc1a forward: 5'- AACCACACCCACAGGATCAGA -3'; Pgc1a reverse: 5'-
614 TCTTCGCTTTATTGCTCCATGA - 3'

615 Dio2 forward: 5' - CCACCTGACCACCTTTCCTACT - 3'; Dio2 reverse: 5'-
616 TGGTTCCGGTGCTTCTTAAC -3'

617 Adrb3 forward: 5'- CGACATGTTCTCCACAAATCA -3'; Adrb3 reverse: 5'-

618 TGGATTCCTGCTCTCAAACCTA ACC- 3'

619

620 **Preparation of gene-specific shRNA and shRNA virus**

621 The shRNA sequences for scrambled, MAOB were adopted from previous studies (Nam et al.,

622 2020; Yoon *et al.*, 2014). The shRNA sequence for Gabra5 was designed with BLOCK-iT RNAi

623 Designer (Invitrogen, USA) and cloned into pSicoR lentiviral vectors as previously described (Woo

624 et al., 2012). pSicoR vectors were utilized for plasmid-based shRNA expression *in vitro*. Gabra5

625 shRNA was prepared from Human embryonic kidney 293T (HEK293T) cell which were purchased

626 from ATCC (#CRL-3216, ATCC). Cell were cultured in Dulbecco's modified Eagle's medium

627 (DMEM, Gibco, USA) supplemented with 25 mM of glucose, 4 mM of L-glutamine, 1 mM of sodium

628 pyruvate, 10% heat-inactivated fetal bovine serum (#10082-147, Gibco) and 10,000 units/ml

629 penicillin-streptomycin (#15140-122, Gibco). Cultures were maintained at 37°C in a humidified

630 atmosphere containing 95% air and 5% CO₂. Cells were transfected with DNA clone by transfection

631 reagent (Effectene, #301425, Qiagen). Every construct was verified with sequencing after cloning.

632 Cloned shRNA constructs were packaged into Lentiviruses in IBS Virus Facility

633 (<http://ibs.re.kr/virusfacility>) and KIST Virus Facility (<http://virus.kist.re.kr>).

634 Sequence of scrambled shRNA for control: 5'-TCGCATAGCGTATGCCGTT-3'

635 Antisense sequence of shRNA target for MAOB: 5'-AATCGTAAGATACGATTCTGG-3'

636 Antisense sequence of shRNA target for Gabra5: 5'-CTTAAACCGCAGCCTTTCATC-3'

637

638 **PRV inoculation**

639 Recombinant pseudorabies virus (PRV) inoculation was performed in a biosafety level-2 operating

640 room. For polysynaptic and retrograde circuit mapping from interscapular BAT and inguinal WAT,

641 mice were anesthetized with vaporized isoflurane and settled in a brain stereotaxic apparatus (RWD

642 Life Science Co.). After the interscapular BAT or inguinal WAT were exposed, two 500- μ l injections

643 of a PRV-CAG-EGFP were made into the brown fat or white fat on one side using a Hamilton

644 syringe (KD Scientific). Shortly after surgery, mice were translocated to their home cages. After 5
645 days of microinjection, the animals were deeply anesthetized and then transcardially perfused and
646 processed for immunohistochemistry.

647

648 **Drug administration**


649 KDS2010, a MAOB inhibitor, was synthesized as previously described (Park et al., 2019). To test the
650 effect of KDS2010 in HFD mice, we administered KDS2010 for 7-8 weeks through dissolving the
651 compound in drinking water. The amount of KDS2010 was calculated as 20 mg/kg daily. Selegiline
652 was dissolved in drinking water as calculated at 10 mg/kg daily as previously described (Jo *et al.*,
653 2014). To test the effect of KDS1524 compared with KDS2010 in HFD mice, we intraperitoneally
654 administered 30 mg/kg for each drug for 15 days.

655

656 **QUANTIFICATION AND STATISTICAL ANALYSIS**

657 All analysis were done blindly. The number of experimental samples, mean and SEM values are
658 listed in Table S1. The numbers and individual dots refer to the number of cells unless otherwise
659 clarified in figure legends. For data presentation and statistical analysis, Graphpad Prism
660 (GraphPad Software) was used. For electrophysiology, Minianalysis (synaptosoft) and Clampfit
661 (Molecular Devices) were used. For f, Oxymax for Windows software was used. For image analysis,
662 Imagej and IMARIS softwares were used. Statistical significance was set at * $p < 0.05$, ** $p < 0.01$,
663 *** $p < 0.001$, **** $p < 0.0001$. Data are presented as mean \pm SEM.

664 **SUPPLEMENTAL INFORMATION**



665

666 **Figure S1. Inhibition of Gabra5^{LHA} neurons by DREADD. Related to Figure 2.**

667 (A) Representative images of AAV-Gabra5-eGFP-cre expression in LHA. Scale bar, 100 μm. (B)

668 Gabra5:mCherry mice were injected with AAV-Gabra5-eGFP-cre and cre-activatable AAV carrying

669 mCh (AAV-hSyn-DIO-mCh). Gabra5:hM4Di mice were injected with AAV-Gabra5-eGFP-cre and

670 AAV-hSyn-DIO-hM4Di-mCh. Both groups were CNO drinking. c-Fos is shown as Magenta. Scale

671 bar, 20 μm. (C and D) Percentage of Fos and Gabra5-double-positive neurons was lower in


672 Gabra5:hM4Di than Gabra5:mCherry mice (n = 3-4 mice per group, n = 10, 10 slices, respectively).

673 Fos expression in Gabra5-positive neuron was lower in Gabra5:hM4Di than Gabra5:mCherry mice.

674 (n = 3-4 mice per group, n = 638, 464 cells, respectively).

675


676



677

678 **Figure S2. Development and validation of shRNAs for Gabra5 *in vitro*. and *in vivo*. Related to**
 679 **Figure 3.**

680 (A) Candidate sequences for Gabra5 shRNA are shown with vector information. Each shRNA was
 681 cloned in pSicoR vector to express under U6 promoter together with a cytomegalovirus (CMV)
 682 promoter driving expression of mCherry reporter gene. (B) Fluorescence images of HEK293-T cells
 683 co-transfected with Gabra5 shRNA (shRNA-mCh) with Gabra5 full clone (Gabra5-eGFP). Top,
 684 Scrambled shRNA-mCherry was co-transfected with Gabra5-GFP. Bottom, Candidate 1 or
 685 candidate 2 of Gabra5 shRNA was co-transfected with Gabra5-eGFP. Scale bar, 100 μ m. (C)
 686 Knock-down rate of Gabra5 shRNA candidates compared to scrambled shRNA by RT-PCR. (D)
 687 Tom, Bottom, Gabra5-shRNA carrying lenti virus express mCherry in LHA. Scale bar, 100 μ m. (E)
 688 Gabra5-IR was shown in GFP. Scale bar, 20 μ m. Scale bar, 10 μ m. (F) Expression of Gabra5 in
 689 mCherry-positive cell was significantly lower in shGabra5 mice compared to Scrambled mice (n=
 690 96, 64 cells, respectively).



691

692 **Figure S3. Expression of iBAT- and iWAT innervating neurons in LHA and expression of**
693 **Gabra5^{LHA}. Related to Figure 3 and Figure 4.**

694 (A) We injected PRV-eGFP virus in iBAT and iWAT. After 5 days, mice showed robust expression of

695 GFP-positive cells along the AP axis of LHA, from AP -1.34 mm to AP -1.94 mm. Scale bar, 100

696 μ m. (B) Experimental schema of AAV-Gabra5-eGFP-cre virus injection and sagittal view of mouse

697 brain. (C) Left, ventral view of the mouse brain from 3D Allen brain atlas. LHA is colored by green


698 and PAG is colored by magenta. White rectangle indicates region of interest. Right, ventral image of

699 LHA-injected mice with AAV-Gabra5-eGFP-cre virus. Scale bar, 300 μ m. (D) Gabra5 expression in

700 LHA of Chow and HFD mice. (E) The expression level of Gabra5 in medial, central and lateral part

701 of the LHA was not significantly changed in HFD mice compared to Chow mice. Scale bar, 20 μ m.

702 Scale bar, 5 μ m.



703


704 **Figure S4. Knockdown of astrocytic GABA by gene-silencing. Related to Figure 5.**

705 (A) Top, schematic diagram. Bottom, *Gabra5*-shRNA carrying lenti virus express mCherry in LHA.

706 Scale bar, 100 μ m. (B) MAOB-IR was shown in GFP. Scale bar, 20 μ m. Scale bar, 15 μ m. (C)

707 Expression of MAOB in GFAP-positive astrocyte was significantly lower in shMAOB mice compared

708 to Scrambled mice (n=697, 345 cells, respectively).



709

710 **Figure S5. Inhibition of irreversible MAOB, Selegiline and less-BBB-permeable MAOB,**

711 **KDS1524. Related to Figure 6.**

712 (A) Curves representing the kinetics of change in body weight among HFD, HFD with KDS2010,

713 and HFD with selegiline mice over the 22 weeks following HFD treatment. Light blue box means

714 KDS2010 or selegiline treatment in drinking water. n= 8 mice per group. (B) Cumulative food intake

715 in HFD, HFD with KDS2010, HFD with selegiline mice over the 22 weeks. n=8 mice per group. (C

716 and D) Quantification of percentage change of fat mass (C) and lean mass (D) at before (15 week)

717 and after (22 week) KDS2010 or selegiline treatment. (E) Chemical structure of KDS1524. (F)


718 Cerebrospinal fluid (CSF) concentration after intravenous and oral administration at a dose of 5, 10

719 mg/kg of KDS1524 (n= 4 mice). KDS1524 cannot pass the blood-brain-barrier. (G) Curves

720 representing the kinetics of change in body weight in gram of chow, HFD, HFD with KDS1524 and

721 HFD with KDS2010 mice over 16 days following HFD treatment. KDS2010 or KDS1524 was

722 administered by oral injection (n= 8, 8, 8, 6 mice, respectively). (H) Curves representing the kinetics
723 of change in body increase in percentage of chow, HFD, HFD with KDS1524 and HFD with
724 KDS2010 mice. (I) Quantification of percentage change of body increase of HFD with KDS1524 and
725 HFD with KDS2010 compared to HFD mice.




726

727 **Figure S6. KDS2010 reduces fats, glucose tolerance and astrocytic GABA. Related to Figure**
 728 **7.**

729 (A) Representative images of each organ of chow, chow with KDS2010, HFD, HFD with KDS2010
 730 mice. Scale bar, 1 cm. (B) Time course of blood glucose levels during the oral glucose tolerance
 731 test (GTT) of chow, chow with KDS2010, HFD, HFD with KDS2010 mice. The mean glucose
 732 concentrations during the GTT were compared using Tukey's multiple comparisons test at different
 733 time points (30, 60, 90 and 120 min). (** $p < 0.001$, **** $p < 0.0001$, HFD vs. HFD with KDS2010;
 734 # $p < 0.05$, Chow vs. Chow with KDS2010) $n = 7-10$ mice per group. (C) Quantification of area under
 735 curve (AUC) of glucose tolerance test. (D) Time course of blood glucose levels during the insulin
 736 tolerance test (ITT) of chow, chow with KDS2010, HFD, HFD with KDS2010 mice. The mean
 737 glucose concentrations during the ITT were compared using Tukey's multiple comparisons test at
 738 different time points (30, 60, 90 and 120 min). (**** $p < 0.0001$, HFD vs. HFD with KDS2010; # $p < 0.05$,

739 Chow vs. Chow with KDS2010) n = 7-10 mice per group. (E) Quantification of area under curve
740 (AUC) of insulin tolerance test. (F) Immunostaining for MAOB and GFAP in LHA of chow, chow with
741 KDS2010, HFD and HFD with KDS2010 group. Scale bar, 10 μ m. (G) MAOB intensity in GFAP-
742 positive cells in chow, chow with KDS2010, HFD and HFD with KDS2010 group. n = 3-4 per group,
743 n = 464, 463, 383, 296 cells, respectively.



744

745 **Figure S7. Summary. Related to Discussion part.**

746 (A) In DIO mouse model, GABA-synthesizing enzyme, MAOB, increased in reactive astrocytes of
747 LHA. Chronic HFD leads to enhanced fatty acids in the blood which can increase oxidative or ER
748 stress and inflammatory responses. Increased MAOB synthesize more GABA in reactive astrocytes,
749 may tonically suppress the activity of Gabra5LHA. Inhibition of pacemaker firing GABAergic
750 Gabra5LHA attenuate energy expenditure and finally exacerbate obesity by decreasing
751 thermogenesis and lipolysis-related gene expression in BAT and WAT. (B) Whereas the elevated
752 tonic GABA or MAOB in hypothalamus of DIO mouse model, can be restored to the normal level by

- 753 MAOB knockdown or Gabra5 knockdown or KDS2010 treatment. Emancipation of inhibition in
754 pacemaker firing of Gabra5^{LHA} facilitates energy expenditure and then prevents obesity.

755 **REFERENCES**

- 756 Backberg, M., Ultenius, C., Fritschy, J.M., and Meister, B. (2004). Cellular localization of GABA
757 receptor alpha subunit immunoreactivity in the rat hypothalamus: relationship with neurones
758 containing orexigenic or anorexigenic peptides. *J Neuroendocrinol* *16*, 589-604. 10.1111/j.1365-
759 2826.2004.01207.x.
- 760 Bamshad, M., Song, C.K., and Bartness, T.J. (1999). CNS origins of the sympathetic nervous
761 system outflow to brown adipose tissue. *Am J Physiol* *276*, R1569-1578.
762 10.1152/ajpregu.1999.276.6.R1569.
- 763 Bartness, T.J., Kay Song, C., Shi, H., Bowers, R.R., and Foster, M.T. (2005). Brain-adipose tissue
764 cross talk. *Proc Nutr Soc* *64*, 53-64. 10.1079/pns2004409.
- 765 Bartness, T.J., Vaughan, C.H., and Song, C.K. (2010). Sympathetic and sensory innervation of
766 brown adipose tissue. *Int J Obes (Lond)* *34 Suppl 1*, S36-42. 10.1038/ijo.2010.182.
- 767 Bernardis, L.L., and Bellinger, L.L. (1993). The lateral hypothalamic area revisited: neuroanatomy,
768 body weight regulation, neuroendocrinology and metabolism. *Neurosci Biobehav Rev* *17*, 141-193.
769 10.1016/s0149-7634(05)80149-6.
- 770 Berthoud, H.R., Patterson, L.M., Sutton, G.M., Morrison, C., and Zheng, H. (2005). Orexin inputs to
771 caudal raphe neurons involved in thermal, cardiovascular, and gastrointestinal regulation.
772 *Histochem Cell Biol* *123*, 147-156. 10.1007/s00418-005-0761-x.
- 773 Bhattarai, J.P., Park, S.A., Park, J.B., Lee, S.Y., Herbison, A.E., Ryu, P.D., and Han, S.K. (2011).
774 Tonic extrasynaptic GABA(A) receptor currents control gonadotropin-releasing hormone neuron
775 excitability in the mouse. *Endocrinology* *152*, 1551-1561. 10.1210/en.2010-1191.
- 776 Bittencourt, J.C. (2011). Anatomical organization of the melanin-concentrating hormone peptide
777 family in the mammalian brain. *Gen Comp Endocrinol* *172*, 185-197. 10.1016/j.ygcen.2011.03.028.
- 778 Bonnavion, P., Mickelsen, L.E., Fujita, A., de Lecea, L., and Jackson, A.C. (2016). Hubs and spokes
779 of the lateral hypothalamus: cell types, circuits and behaviour. *J Physiol* *594*, 6443-6462.
780 10.1113/JP271946.

781 Bouyakdan, K., Martin, H., Lienard, F., Budry, L., Taib, B., Rodaros, D., Chretien, C., Biron, E.,
782 Husson, Z., Cota, D., et al. (2019). The gliotransmitter ACBP controls feeding and energy
783 homeostasis via the melanocortin system. *J Clin Invest* 129, 2417-2430. 10.1172/JCI123454.
784 Brickley, S.G., and Mody, I. (2012). Extrasynaptic GABA(A) receptors: their function in the CNS and
785 implications for disease. *Neuron* 73, 23-34. 10.1016/j.neuron.2011.12.012.
786 Buckman, L.B., Thompson, M.M., Moreno, H.N., and Ellacott, K.L. (2013). Regional astrogliosis in
787 the mouse hypothalamus in response to obesity. *J Comp Neurol* 521, 1322-1333.
788 10.1002/cne.23233.
789 Burdakov, D., and Karnani, M.M. (2020). Ultra-sparse Connectivity within the Lateral Hypothalamus.
790 *Curr Biol* 30, 4063-4070 e4062. 10.1016/j.cub.2020.07.061.
791 Cannon, B., and Nedergaard, J. (2004). Brown adipose tissue: function and physiological
792 significance. *Physiol Rev* 84, 277-359. 10.1152/physrev.00015.2003.
793 Cao, L., Choi, E.Y., Liu, X., Martin, A., Wang, C., Xu, X., and Daring, M.J. (2011). White to brown fat
794 phenotypic switch induced by genetic and environmental activation of a hypothalamic-adipocyte
795 axis. *Cell Metab* 14, 324-338. 10.1016/j.cmet.2011.06.020.
796 Caraiscos, V.B., Elliott, E.M., You-Ten, K.E., Cheng, V.Y., Belelli, D., Newell, J.G., Jackson, M.F.,
797 Lambert, J.J., Rosahl, T.W., Wafford, K.A., et al. (2004). Tonic inhibition in mouse hippocampal CA1
798 pyramidal neurons is mediated by alpha5 subunit-containing gamma-aminobutyric acid type A
799 receptors. *Proc Natl Acad Sci U S A* 101, 3662-3667. 10.1073/pnas.0307231101.
800 Cero, C., Lea, H.J., Zhu, K.Y., Shamsi, F., Tseng, Y.H., and Cypess, A.M. (2021). beta3-Adrenergic
801 receptors regulate human brown/beige adipocyte lipolysis and thermogenesis. *JCI Insight* 6.
802 10.1172/jci.insight.139160.
803 Cerri, M., and Morrison, S.F. (2005). Activation of lateral hypothalamic neurons stimulates brown
804 adipose tissue thermogenesis. *Neuroscience* 135, 627-638. 10.1016/j.neuroscience.2005.06.039.
805 Chari, M., Yang, C.S., Lam, C.K., Lee, K., Mighiu, P., Kokorovic, A., Cheung, G.W., Lai, T.Y., Wang,
806 P.Y., and Lam, T.K. (2011). Glucose transporter-1 in the hypothalamic glial cells mediates glucose
807 sensing to regulate glucose production in vivo. *Diabetes* 60, 1901-1906. 10.2337/db11-0120.

- 808 Chen, N., Sugihara, H., Kim, J., Fu, Z., Barak, B., Sur, M., Feng, G., and Han, W. (2016). Direct
809 modulation of GFAP-expressing glia in the arcuate nucleus bi-directionally regulates feeding. *Elife*
810 *5*. 10.7554/eLife.18716.
- 811 Cheung, B.M., Cheung, T.T., and Samaranayake, N.R. (2013). Safety of antiobesity drugs. *Ther*
812 *Adv Drug Saf* *4*, 171-181. 10.1177/2042098613489721.
- 813 Chun, H., An, H., Lim, J., Woo, J., Lee, J., Ryu, H., and Lee, C.J. (2018). Astrocytic proBDNF and
814 Tonic GABA Distinguish Active versus Reactive Astrocytes in Hippocampus. *Exp Neurobiol* *27*, 155-
815 170. 10.5607/en.2018.27.3.155.
- 816 Chun, H., Im, H., Kang, Y.J., Kim, Y., Shin, J.H., Won, W., Lim, J., Ju, Y., Park, Y.M., Kim, S., et al.
817 (2020a). Severe reactive astrocytes precipitate pathological hallmarks of Alzheimer's disease via
818 H₂O₂- production. *Nat Neurosci* *23*, 1555-U1542. 10.1038/s41593-020-00735-y.
- 819 Chun, H., Im, H., Kang, Y.J., Kim, Y., Shin, J.H., Won, W., Lim, J., Ju, Y., Park, Y.M., Kim, S., et al.
820 (2020b). Severe reactive astrocytes precipitate pathological hallmarks of Alzheimer's disease via
821 H₂O₂(-) production. *Nat Neurosci* *23*, 1555-1566. 10.1038/s41593-020-00735-y.
- 822 Chun, H., and Lee, C.J. (2018). Reactive astrocytes in Alzheimer's disease: A double-edged sword.
823 *Neurosci Res* *126*, 44-52. 10.1016/j.neures.2017.11.012.
- 824 Chun, H., Lim, J., Park, K.D., and Lee, C.J. (2021). Inhibition of monoamine oxidase B prevents
825 reactive astrogliosis and scar formation in stab wound injury model. *Glia*. 10.1002/glia.24110.
- 826 Contreras, C., Gonzalez, F., Ferno, J., Dieguez, C., Rahmouni, K., Nogueiras, R., and Lopez, M.
827 (2015). The brain and brown fat. *Ann Med* *47*, 150-168. 10.3109/07853890.2014.919727.
- 828 Contreras, C., Nogueiras, R., Dieguez, C., Rahmouni, K., and Lopez, M. (2017). Traveling from the
829 hypothalamus to the adipose tissue: The thermogenic pathway. *Redox Biol* *12*, 854-863.
830 10.1016/j.redox.2017.04.019.
- 831 de Vrind, V.A.J., Rozeboom, A., Wolterink-Donselaar, I.G., Luijendijk-Berg, M.C.M., and Adan,
832 R.A.H. (2019). Effects of GABA and Leptin Receptor-Expressing Neurons in the Lateral
833 Hypothalamus on Feeding, Locomotion, and Thermogenesis. *Obesity (Silver Spring)* *27*, 1123-
834 1132. 10.1002/oby.22495.

835 Elias, C.F., Sita, L.V., Zambon, B.K., Oliveira, E.R., Vasconcelos, L.A., and Bittencourt, J.C. (2008).
836 Melanin-concentrating hormone projections to areas involved in somatomotor responses. *J Chem*
837 *Neuroanat* 35, 188-201. 10.1016/j.jchemneu.2007.10.002.

838 Farrant, M., and Nusser, Z. (2005). Variations on an inhibitory theme: phasic and tonic activation of
839 GABA(A) receptors. *Nat Rev Neurosci* 6, 215-229. 10.1038/nrn1625.

840 Flament-Durand, J. (1980). The hypothalamus: anatomy and functions. *Acta Psychiatr Belg* 80,
841 364-375.

842 Garcia-Caceres, C., Quarta, C., Varela, L., Gao, Y., Gruber, T., Legutko, B., Jastroch, M.,
843 Johansson, P., Ninkovic, J., Yi, C.X., et al. (2016). Astrocytic Insulin Signaling Couples Brain
844 Glucose Uptake with Nutrient Availability. *Cell* 166, 867-880. 10.1016/j.cell.2016.07.028.

845 Gonzalez-Garcia, I., and Garcia-Caceres, C. (2021). Hypothalamic Astrocytes as a Specialized and
846 Responsive Cell Population in Obesity. *Int J Mol Sci* 22. 10.3390/ijms22126176.

847 Harthoorn, L.F., Sane, A., Nethe, M., and Van Heerikhuize, J.J. (2005). Multi-transcriptional profiling
848 of melanin-concentrating hormone and orexin-containing neurons. *Cell Mol Neurobiol* 25, 1209-
849 1223. 10.1007/s10571-005-8184-8.

850 Hassani, O.K., Henny, P., Lee, M.G., and Jones, B.E. (2010). GABAergic neurons intermingled with
851 orexin and MCH neurons in the lateral hypothalamus discharge maximally during sleep. *Eur J*
852 *Neurosci* 32, 448-457. 10.1111/j.1460-9568.2010.07295.x.

853 Heo, J.Y., Nam, M.H., Yoon, H.H., Kim, J., Hwang, Y.J., Won, W., Woo, D.H., Lee, J.A., Park, H.J.,
854 Jo, S., et al. (2020). Aberrant Tonic Inhibition of Dopaminergic Neuronal Activity Causes Motor
855 Symptoms in Animal Models of Parkinson's Disease. *Curr Biol* 30, 276-291 e279.
856 10.1016/j.cub.2019.11.079.

857 Hortnagl, H., Tasan, R.O., Wieselthaler, A., Kirchmair, E., Sieghart, W., and Sperk, G. (2013).
858 Patterns of mRNA and protein expression for 12 GABAA receptor subunits in the mouse brain.
859 *Neuroscience* 236, 345-372. 10.1016/j.neuroscience.2013.01.008.

860 Izawa, S., Yoneshiro, T., Kondoh, K., Nakagiri, S., Okamatsu-Ogura, Y., Terao, A., Minokoshi, Y.,
861 Yamanaka, A., and Kimura, K. (2021). Melanin-concentrating hormone-producing neurons in the

862 hypothalamus regulate brown adipose tissue and thus contribute to energy expenditure. *J Physiol.*
863 10.1113/JP281241.

864 Jennings, J.H., Rizzi, G., Stamatakis, A.M., Ung, R.L., and Stuber, G.D. (2013). The inhibitory circuit
865 architecture of the lateral hypothalamus orchestrates feeding. *Science* 341, 1517-1521.
866 10.1126/science.1241812.

867 Jennings, J.H., Ung, R.L., Resendez, S.L., Stamatakis, A.M., Taylor, J.G., Huang, J., Veleta, K.,
868 Kantak, P.A., Aita, M., Shilling-Scriver, K., et al. (2015). Visualizing hypothalamic network dynamics
869 for appetitive and consummatory behaviors. *Cell* 160, 516-527. 10.1016/j.cell.2014.12.026.

870 Jo, S., Yarishkin, O., Hwang, Y.J., Chun, Y.E., Park, M., Woo, D.H., Bae, J.Y., Kim, T., Lee, J.,
871 Chun, H., et al. (2014). GABA from reactive astrocytes impairs memory in mouse models of
872 Alzheimer's disease. *Nat Med* 20, 886-896. 10.1038/nm.3639.

873 Kakizaki, M., Tsuneoka, Y., Takase, K., Kim, S.J., Choi, J., Ikkyu, A., Abe, M., Sakimura, K.,
874 Yanagisawa, M., and Funato, H. (2019). Differential Roles of Each Orexin Receptor Signaling in
875 Obesity. *iScience* 20, 1-13. 10.1016/j.isci.2019.09.003.

876 Karnani, M.M., Szabo, G., Erdelyi, F., and Burdakov, D. (2013). Lateral hypothalamic GAD65
877 neurons are spontaneously firing and distinct from orexin- and melanin-concentrating hormone
878 neurons. *J Physiol* 591, 933-953. 10.1113/jphysiol.2012.243493.

879 Kim, G.W., Lin, J.E., Blomain, E.S., and Waldman, S.A. (2014a). Antiobesity pharmacotherapy: new
880 drugs and emerging targets. *Clin Pharmacol Ther* 95, 53-66. 10.1038/clpt.2013.204.

881 Kim, J.G., Suyama, S., Koch, M., Jin, S., Argente-Arizon, P., Argente, J., Liu, Z.W., Zimmer, M.R.,
882 Jeong, J.K., Szigeti-Buck, K., et al. (2014b). Leptin signaling in astrocytes regulates hypothalamic
883 neuronal circuits and feeding. *Nat Neurosci* 17, 908-910. 10.1038/nn.3725.

884 Kong, D., Tong, Q., Ye, C., Koda, S., Fuller, P.M., Krashes, M.J., Vong, L., Ray, R.S., Olson, D.P.,
885 and Lowell, B.B. (2012). GABAergic RIP-Cre neurons in the arcuate nucleus selectively regulate
886 energy expenditure. *Cell* 151, 645-657. 10.1016/j.cell.2012.09.020.

- 887 Kosse, C., Schone, C., Bracey, E., and Burdakov, D. (2017). Orexin-driven GAD65 network of the
888 lateral hypothalamus sets physical activity in mice. *Proc Natl Acad Sci U S A* *114*, 4525-4530.
889 10.1073/pnas.1619700114.
- 890 Kurylowicz, A., Jonas, M., Lisik, W., Jonas, M., Wicik, Z.A., Wierzbicki, Z., Chmura, A., and
891 Puzianowska-Kuznicka, M. (2015). Obesity is associated with a decrease in expression but not with
892 the hypermethylation of thermogenesis-related genes in adipose tissues. *J Transl Med* *13*, 31.
893 10.1186/s12967-015-0395-2.
- 894 Kwak, H., Koh, W., Kim, S., Song, K., Shin, J.-I., Lee, J.M., Lee, E.H., Bae, J.Y., Ha, G.E., and Oh,
895 J.-E. (2020). Astrocytes control sensory acuity via tonic inhibition in the thalamus. *Neuron* *108*, 691-
896 706. e610.
- 897 Lee, J., Raycraft, L., and Johnson, A.W. (2021). The dynamic regulation of appetitive behavior
898 through lateral hypothalamic orexin and melanin concentrating hormone expressing cells. *Physiol*
899 *Behav* *229*, 113234. 10.1016/j.physbeh.2020.113234.
- 900 Lee, N., Sa, M., Hong, Y.R., Lee, C.J., and Koo, J. (2018). Fatty Acid Increases cAMP-dependent
901 Lactate and MAO-B-dependent GABA Production in Mouse Astrocytes by Activating a Galphas
902 Protein-coupled Receptor. *Exp Neurobiol* *27*, 365-376. 10.5607/en.2018.27.5.365.
- 903 Lee, S., Yoon, B.E., Berglund, K., Oh, S.J., Park, H., Shin, H.S., Augustine, G.J., and Lee, C.J.
904 (2010). Channel-mediated tonic GABA release from glia. *Science* *330*, 790-796.
905 10.1126/science.1184334.
- 906 Lizarbe, B., Cherix, A., Duarte, J.M.N., Cardinaux, J.R., and Gruetter, R. (2019). High-fat diet
907 consumption alters energy metabolism in the mouse hypothalamus. *Int J Obes (Lond)* *43*, 1295-
908 1304. 10.1038/s41366-018-0224-9.
- 909 McDougal, D.H., Hermann, G.E., and Rogers, R.C. (2013). Astrocytes in the nucleus of the solitary
910 tract are activated by low glucose or glucoprivation: evidence for glial involvement in glucose
911 homeostasis. *Front Neurosci* *7*, 249. 10.3389/fnins.2013.00249.

912 Moraes, J.C., Coope, A., Morari, J., Cintra, D.E., Roman, E.A., Pauli, J.R., Romanatto, T.,
913 Carvalheira, J.B., Oliveira, A.L., Saad, M.J., and Velloso, L.A. (2009). High-fat diet induces
914 apoptosis of hypothalamic neurons. *PLoS One* 4, e5045. 10.1371/journal.pone.0005045.
915 Morrison, S.F., Madden, C.J., and Tupone, D. (2012). Central control of brown adipose tissue
916 thermogenesis. *Front Endocrinol (Lausanne)* 3. 10.3389/fendo.2012.00005.
917 Morrison, S.F., Madden, C.J., and Tupone, D. (2014). Central neural regulation of brown adipose
918 tissue thermogenesis and energy expenditure. *Cell Metab* 19, 741-756.
919 10.1016/j.cmet.2014.02.007.
920 Nam, M.H., Cho, J., Kwon, D.H., Park, J.Y., Woo, J., Lee, J.M., Lee, S., Ko, H.Y., Won, W., Kim,
921 R.G., et al. (2020). Excessive Astrocytic GABA Causes Cortical Hypometabolism and Impedes
922 Functional Recovery after Subcortical Stroke. *Cell Rep* 32, 107861. 10.1016/j.celrep.2020.107861.
923 Nam, M.H., Park, J.H., Song, H.J., Choi, J.W., Kim, S., Jang, B.K., Yoon, H.H., Heo, J.Y., Lee, H.,
924 An, H., et al. (2021). KDS2010, a Newly Developed Reversible MAO-B Inhibitor, as an Effective
925 Therapeutic Candidate for Parkinson's Disease. *Neurotherapeutics*. 10.1007/s13311-021-01097-4.
926 Nguyen, N.L., Randall, J., Banfield, B.W., and Bartness, T.J. (2014). Central sympathetic
927 innervations to visceral and subcutaneous white adipose tissue. *Am J Physiol Regul Integr Comp*
928 *Physiol* 306, R375-386. 10.1152/ajpregu.00552.2013.
929 Oldfield, B.J., Giles, M.E., Watson, A., Anderson, C., Colvill, L.M., and McKinley, M.J. (2002). The
930 neurochemical characterisation of hypothalamic pathways projecting polysynaptically to brown
931 adipose tissue in the rat. *Neuroscience* 110, 515-526. 10.1016/s0306-4522(01)00555-3.
932 Orozco-Solis, R., Aguilar-Arnal, L., Murakami, M., Peruquetti, R., Ramadori, G., Coppari, R., and
933 Sassone-Corsi, P. (2016). The Circadian Clock in the Ventromedial Hypothalamus Controls Cyclic
934 Energy Expenditure. *Cell Metab* 23, 467-478. 10.1016/j.cmet.2016.02.003.
935 Palkovits, M., Makara, G.B., Leranath, C., and Van Cuc, H. (1980). Intrahypothalamic terminals of
936 stress conducting fibers. *Brain Res* 190, 399-407. 10.1016/0006-8993(80)90282-6.
937 Pandit, S., Neupane, C., Woo, J., Sharma, R., Nam, M.H., Lee, G.S., Yi, M.H., Shin, N., Kim, D.W.,
938 Cho, H., et al. (2020). Bestrophin1-mediated tonic GABA release from reactive astrocytes prevents

939 the development of seizure-prone network in kainate-injected hippocampi. *Glia* 68, 1065-1080.
940 10.1002/glia.23762.

941 Park, J.H., Ju, Y.H., Choi, J.W., Song, H.J., Jang, B.K., Woo, J., Chun, H., Kim, H.J., Shin, S.J.,
942 Yarishkin, O., et al. (2019). Newly developed reversible MAO-B inhibitor circumvents the
943 shortcomings of irreversible inhibitors in Alzheimer's disease. *Sci Adv* 5, eaav0316.
944 10.1126/sciadv.aav0316.

945 Park, Y.G., Sohn, C.H., Chen, R., McCue, M., Yun, D.H., Drummond, G.T., Ku, T., Evans, N.B.,
946 Oak, H.C., Trieu, W., et al. (2018). Protection of tissue physicochemical properties using
947 polyfunctional crosslinkers. *Nat Biotechnol.* 10.1038/nbt.4281.

948 Recena Aydos, L., Aparecida do Amaral, L., Serafim de Souza, R., Jacobowski, A.C., Freitas Dos
949 Santos, E., and Rodrigues Macedo, M.L. (2019). Nonalcoholic Fatty Liver Disease Induced by High-
950 Fat Diet in C57bl/6 Models. *Nutrients* 11. 10.3390/nu11123067.

951 Richard, D., and Picard, F. (2011). Brown fat biology and thermogenesis. *Front Biosci (Landmark*
952 *Ed)* 16, 1233-1260. 10.2741/3786.

953 Rossi, M.A., Basiri, M.L., McHenry, J.A., Kosyk, O., Otis, J.M., van den Munkhof, H.E., Bryois, J.,
954 Hubel, C., Breen, G., Guo, W., et al. (2019). Obesity remodels activity and transcriptional state of a
955 lateral hypothalamic brake on feeding. *Science* 364, 1271-1274. 10.1126/science.aax1184.

956 Ryu, V., Garretson, J.T., Liu, Y., Vaughan, C.H., and Bartness, T.J. (2015). Brown adipose tissue
957 has sympathetic-sensory feedback circuits. *J Neurosci* 35, 2181-2190. 10.1523/JNEUROSCI.3306-
958 14.2015.

959 Ryu, V., Watts, A.G., Xue, B., and Bartness, T.J. (2017). Bidirectional crosstalk between the
960 sensory and sympathetic motor systems innervating brown and white adipose tissue in male
961 Siberian hamsters. *Am J Physiol Regul Integr Comp Physiol* 312, R324-R337.
962 10.1152/ajpregu.00456.2015.

963 Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R.M., Tanaka, H., Williams, S.C.,
964 Richardson, J.A., Kozlowski, G.P., Wilson, S., et al. (1998). Orexins and orexin receptors: a family

965 of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. *Cell*
966 *92*, 573-585. 10.1016/s0092-8674(00)80949-6.

967 Schneeberger, M., Parolari, L., Das Banerjee, T., Bhave, V., Wang, P., Patel, B., Topilko, T., Wu, Z.,
968 Choi, C.H.J., Yu, X., et al. (2019). Regulation of Energy Expenditure by Brainstem GABA Neurons.
969 *Cell* *178*, 672-685 e612. 10.1016/j.cell.2019.05.048.

970 Shim, H.S., Park, H.J., Woo, J., Lee, C.J., and Shim, I. (2019). Role of astrocytic GABAergic system
971 on inflammatory cytokine-induced anxiety-like behavior. *Neuropharmacology* *160*, 107776.
972 10.1016/j.neuropharm.2019.107776.

973 Shin, S.Y., Yang, J.H., Lee, H., Erdelyi, F., Szabo, G., Lee, S.Y., and Ryu, P.D. (2007). Identification
974 of the adrenoceptor subtypes expressed on GABAergic neurons in the anterior hypothalamic area
975 and rostral zona incerta of GAD65-eGFP transgenic mice. *Neurosci Lett* *422*, 153-157.
976 10.1016/j.neulet.2007.05.060.

977 Stuber, G.D., and Wise, R.A. (2016). Lateral hypothalamic circuits for feeding and reward. *Nat*
978 *Neurosci* *19*, 198-205. 10.1038/nn.4220.

979 Thaler, J.P., Yi, C.X., Schur, E.A., Guyenet, S.J., Hwang, B.H., Dietrich, M.O., Zhao, X., Sarruf,
980 D.A., Izgur, V., Maravilla, K.R., et al. (2012). Obesity is associated with hypothalamic injury in
981 rodents and humans. *J Clin Invest* *122*, 153-162. 10.1172/JCI59660.

982 Tupone, D., Madden, C.J., Cano, G., and Morrison, S.F. (2011). An orexinergic projection from
983 perifornical hypothalamus to raphe pallidus increases rat brown adipose tissue thermogenesis. *J*
984 *Neurosci* *31*, 15944-15955. 10.1523/JNEUROSCI.3909-11.2011.

985 Varela, L., Stutz, B., Song, J.E., Kim, J.G., Liu, Z.W., Gao, X.B., and Horvath, T.L. (2021). Hunger-
986 promoting AgRP neurons trigger an astrocyte-mediated feed-forward autoactivation loop in mice. *J*
987 *Clin Invest* *131*. 10.1172/JCI144239.

988 Whittle, A.J., Jiang, M., Peirce, V., Relat, J., Virtue, S., Ebinuma, H., Fukamachi, I., Yamaguchi, T.,
989 Takahashi, M., Murano, T., et al. (2015). Soluble LR11/SorLA represses thermogenesis in adipose
990 tissue and correlates with BMI in humans. *Nat Commun* *6*, 8951. 10.1038/ncomms9951.

991 Woo, D.H., Han, K.S., Shim, J.W., Yoon, B.E., Kim, E., Bae, J.Y., Oh, S.J., Hwang, E.M.,
992 Marmorstein, A.D., Bae, Y.C., et al. (2012). TREK-1 and Best1 channels mediate fast and slow
993 glutamate release in astrocytes upon GPCR activation. *Cell* 151, 25-40. 10.1016/j.cell.2012.09.005.
994 Yang, L., Qi, Y., and Yang, Y. (2015). Astrocytes control food intake by inhibiting AGRP neuron
995 activity via adenosine A1 receptors. *Cell Rep* 11, 798-807. 10.1016/j.celrep.2015.04.002.
996 Yoon, B.E., Woo, J., Chun, Y.E., Chun, H., Jo, S., Bae, J.Y., An, H., Min, J.O., Oh, S.J., Han, K.S.,
997 et al. (2014). Glial GABA, synthesized by monoamine oxidase B, mediates tonic inhibition. *J Physiol*
998 592, 4951-4968. 10.1113/jphysiol.2014.278754.
999 Yoon, B.E., Woo, J., and Lee, C.J. (2012). Astrocytes as GABA-ergic and GABA-ceptive cells.
1000 *Neurochem Res* 37, 2474-2479. 10.1007/s11064-012-0808-z.
1001 You, H., Chu, P., Guo, W., and Lu, B. (2020). A subpopulation of Bdnf-e1-expressing glutamatergic
1002 neurons in the lateral hypothalamus critical for thermogenesis control. *Mol Metab* 31, 109-123.
1003 10.1016/j.molmet.2019.11.013.
1004 Zhang, Y., Reichel, J.M., Han, C., Zuniga-Hertz, J.P., and Cai, D. (2017). Astrocytic Process
1005 Plasticity and IKKbeta/NF-kappaB in Central Control of Blood Glucose, Blood Pressure, and Body
1006 Weight. *Cell Metab* 25, 1091-1102 e1094. 10.1016/j.cmet.2017.04.002.
1007 Zink, A.N., Bunney, P.E., Holm, A.A., Billington, C.J., and Kotz, C.M. (2018). Neuromodulation of
1008 orexin neurons reduces diet-induced adiposity. *Int J Obes (Lond)* 42, 737-745.
1009 10.1038/ijo.2017.276.
1010